All News

Investigational Drug Targeting Epstein-Barr Virus Shows Promise for Progressive MS

September 21, 2020

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

Progressive and Relapsing-Remitting Multiple Sclerosis Share Similar Fatigue Severity

September 21, 2020

Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other.

World Alzheimer’s Day 2020: The Latest News and Commentary on the Treatment of Alzheimer Disease

September 21, 2020

In honor of World Alzheimer’s Day, NeurologyLive is sharing some of the latest clinical developments and thoughts from leaders in the field.

Optimal Management of OFF Episodes in Parkinson's Disease

September 21, 2020

Experts review the challenges of managing OFF episodes in Parkinson's disease and the current treatment options to optimize therapy.

The Changing Treatment Landscape for Acute Migraine

September 21, 2020

David Dodick, MD, reviews changes to the treatment landscape for acute migraine.

Jonathan Graff-Radford, MD: Importance of World Alzheimer’s Day

September 21, 2020

The neurologist at Mayo Clinic shared his thoughts on the need to raise awareness of Alzheimer disease on World Alzheimer’s Day.

Ganaxolone Meets Primary End Point in CDKL5 Deficiency Disorder Study

September 20, 2020

Marinus Pharmaceuticals’ positive allosteric GABAA receptor modulator ganaxolone was associated with significant median reductions in 28-day major motor seizure frequency compared to placebo.

Ocrelizumab Treatment Results in High NEDA Rates, Improvements in MS Symptoms

September 19, 2020

A pair of datasets from the phase 3b CASTING study of ocrelizumab (Ocrevus; Genentech) suggest that patients treated with the agent experienced high rates of no evidence of disease activity status regardless of prior DMT exposure.

Opicapone Treats Motor Fluctuations, Directional DBS Favored in PD, MRgFUS is Effective as Hand Tremor Treatment

September 19, 2020

Neurology News Network for the week ending September 19, 2020.

NeurologyLive Friday 5 — September 18, 2020

September 18, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.

Luc Truyen, MD, PhD: Long-Term Results of Ponesimod in Phase 2b Study

September 18, 2020

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed the results of a phase 2 core and extension study of ponesimod in patients with relapsing-remitting multiple sclerosis.

The Metamorphosis of Migraine: Evidence and Epidemiology

September 18, 2020

The ongoing fight to add to the epidemiologic understanding of migraine is explored in part 2 of this special 3-part multimedia series on the evolution of migraine care.

Indu Subramanian, MD: Social Prescribing for Patients With Parkinson Disease

September 18, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers explained how social prescribing can play a key role in the prevention of social isolation.

Ozanimod Shows Long-Term Safety, Efficacy in Open-Label Extension

September 18, 2020

Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.

Sumifilam Improves Multiple Alzheimer Disease Biomarkers in Phase 2b Study

September 17, 2020

The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.

Stewart Factor, MD: Long-Term Data on Apomorphine Sublingual Film in Parkinson

September 17, 2020

The director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine gave his perspective on the interim findings of a long-term safety study of apomorphine sublingual film.

Addressing Loneliness and Social Isolation in Patients With Parkinson Disease

September 17, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD

September 17, 2020

Two posters presented at MS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.

Joaquim Ferreria, MD, PhD: Opicapone’s Use in Levodopa-Treated Patients With Parkinson Disease

September 16, 2020

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

Apomorphine Sublingual Film Shows Long-Term Efficacy in OFF Episode Treatment

September 16, 2020

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

THN102 Is Safe, Improves Excessive Daytime Sleepiness in Parkinson Disease

September 16, 2020

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.

Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MS

September 16, 2020

The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.

Neurology Residency Training During a Pandemic

September 16, 2020

In part 2 of this interview, Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, describes how her resident program experience was impacted by the pandemic.

Mary Schroth, MD: Cure SMA’s Ongoing Advocacy Initiatives

September 15, 2020

The chief medical officer at Cure SMA spoke to the ongoing work that the organization does in advocating for patients with spinal muscular atrophy, particularly for newborn screening.

Amantadine Shows Treatment Durability for Reducing OFF Time in Parkinson Disease

September 15, 2020

The percentage of patients reporting no OFF time and no impact of OFF on daily function more than doubled by the first on-treatment visit in this open-label trial.

Indu Subramanian, MD: The Effect of Loneliness on Parkinson Disease Severity

September 15, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education and Clinical Centers discussed how loneliness can impact Parkinson disease severity and how holistic approaches to care may help.

Tau Levels May Predict Early Disability, Worse Prognosis in MS

September 15, 2020

Data show that higher CSF tau levels at diagnosis correlated with worse disability independent of age, though no such associations were identified with amyloid-beta.

Levodopa-Carbidopa Intestinal Gel Superior to Immediate Release Capsules for ON Time Without Dyskinesia

September 15, 2020

Benefits of levodopa-carbidopa intestinal gel lasted throughout the day and showed greater benefits of continuous dopaminergic stimulation in disease control than immediate release oral capsules.

Opicapone Improves ON, OFF Time in Levodopa-Treated Patients With Parkinson Disease

September 14, 2020

The COMT inhibitor, which was approved in April 2020, may be a worthwhile option as a first-line adjunctive treatment for those with Parkinson disease with motor fluctuations.

Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020

September 14, 2020

Experts in multiple sclerosis review top data presented at the 8th joint ACTRIMS-ECTRIMS meeting.

Levodopa-Carbidopa Intestinal Gel Effective for Dyskinesia in Advanced Parkinson Disease

September 14, 2020

Improvement in dyskinesia occurred after 2 weeks of treatment with levodopa-carbidopa intestinal gel and was sustained throughout the study.

Dravet Syndrome Foundation to Host Virtual Workshop

September 14, 2020

Day of Dravet, a 1-day virtual event on Saturday, October 17th will give attendees an opportunity to meet industry representatives and ask questions.

Ponesimod Linked to Low Levels of Disease Activity in Relapsing Multiple Sclerosis

September 14, 2020

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.

Optimizing Care Transition for Adolescents With Epilepsy

September 14, 2020

Sucheta M. Joshi, MD, MS, and Nicholas Beimer, MD, discuss their experience with EpiTRAQ and the role it can play in optimizing the epilepsy care transition.

NIH Awards Grant to Cleveland Clinic to Establish Alzheimer Disease Research Center

September 14, 2020

The new center is part of the first cohort of centers nationally to receive this new NIH funding and is the first and only in Nevada.

LGS Foundation Hosts 7th International LGS Foundation Family Conference

September 14, 2020

The 7th International LGS Foundation Family Conference features interactive Q&A's, breakout sessions, interactive games, and access to the after party with LGS caregivers.

Join DSF in Taking Steps Toward a Cure

September 14, 2020

Register now to participate in the Dravet Syndrome Foundation's Virtual Steps Toward a cure beginning September 19th.

COVID-19 Has Negative Impact on Parkinson Disease Symptom Management

September 13, 2020

Supporting patient activation of their knowledge, skill, and confidence in managing their health may empower patients in times of stress.

Parkinson Disease Gene Therapy VY-AADC01 Proves Safe With Signs of Efficacy

September 13, 2020

Three-year data from a phase 1 study of Voyager Therapeutics’ VY-AADC01 suggest it is safe and offers potential benefits for patients with Parkinson disease.

Bilateral Focused Ultrasound Thalamotomy Safe, Effective in Essential Tremor

September 12, 2020

Scores reflective of tremor in each body part and task performance improved by 71% in patients from baseline before first thalamotomy to 6 months after second thalamotomy.

Directional Deep Brain Stimulation Linked to Wider Therapeutic Window in Parkinson Disease

September 12, 2020

After 3 months of treatment, an overwhelming number of clinicians and patients preferred directional over omnidirectional DBS.

Cannabinoid May Improve Nonmotor Symptoms in Parkinson Disease

September 12, 2020

Results from a phase 2 pilot study of nabilone in Parkinson disease suggest that the synthetic cannabinoid might hold therapeutic potential for nonmotor symptoms.

NeurologyLive Friday 5 — September 11, 2020

September 11, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 11, 2020.

Ofatumumab Highly Effective in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis

September 11, 2020

Treatment-naïve patients showed consistent results with the overall study population that was observed in the ASCLEPIOS I and II trials.

Episode 17: The Metamorphosis of Migraine: Discovery and Development

September 11, 2020

Mind Moments, a podcast from NeurologyLive, brings you an exclusive interview with Stewart Tepper, MD, in part 1 of this special 3-part multimedia series on the evolution of migraine care.

Disability, Economic Burden Greater in MS Patients With High Levels of Fatigue

September 11, 2020

Patients with relapsing multiple sclerosis and high levels of fatigue were less likely to be employed full-time than those with MS with low fatigue.

Portable, Low-Field MRI Equivalent to Conventional Imaging for Brain Injury

September 10, 2020

Point-of-care, 64mT MRI performs as well as conventional CT and MRI while improving patient safety.

Financial Burden Weighs on Patients With Multiple Sclerosis

September 10, 2020

Financial self-efficacy and having at least 1 relapse were identified as independent predictors of financial toxicity among patients with multiple sclerosis.

Mary Schroth, MD: The Challenge of Early SMA Recognition

September 10, 2020

The chief medical officer at Cure SMA detailed the importance of having options for patients and how certain administration routes and schedules offer more personalized approaches, particularly for adult patients with SMA.

The Psychosocial Impact of COVID-19 in Neurology Departments

September 10, 2020

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.

Sabrina Paganoni, MD, PhD: CENTAUR Trial Open-Label Extension in ALS

September 09, 2020

The investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital spoke to the CENTAUR open-label extension and AMX0035’s development.

Prosetin Gets Orphan Drug Status for ALS

September 09, 2020

The Project ALS-funded oral MAP4 kinase inhibitor has been described in the literature as an exceptionally potent, metabolically stable, and blood-brain barrier-penetrant compound.

Real World and Natural History Data Comparable to Placebo in DMD Trials

September 09, 2020

Researchers noted that the findings are encouraging for the use of real-world data and natural history data to augment, or possibly replace, placebo controls in DMD trials.

Marwan Sabbagh, MD: What’s the Greater Need in Alzheimer, Treatment or Prevention?

September 09, 2020

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic highlighted the most pressing needs within the Alzheimer disease community.

Ketamine Reduces Seizure Burden in Super-Refractory Status Epilepticus

September 09, 2020

Treating patients with super-refractory status epilepticus with ketamine showed no effect on intracranial pressure, cerebral blood flow, and cerebral perfusion pressure.

Overcoming Barriers to Precision Medicine for Parkinson Disease

September 08, 2020

The chief scientific officer at the Parkinson’s Foundation shares his perspective on the current state of Parkinson research and development amid the challenges of the pandemic.

Leah Croll, MD: Psychosocial Implications of COVID-19 on Doctors

September 08, 2020

The neurology resident at NYU Langone described psychosocial implications that physicians faced during the COVID-19 pandemic and the toll it takes on them.

Shai Efrati, MD: Assessing Hyperbaric Oxygen Therapy for Neurodegeneration

September 08, 2020

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center offers takeaways on hyperbaric oxygen therapy.

SSRIs Have Mixed Risks, Benefits in Post-Stroke Recovery

September 08, 2020

Among individuals at high risk for recurrent ICH, the use of selective serotonin reuptake inhibitors was associated with a greater increase in repeated hemorrhagic stroke.

Sabrina Paganoni, MD, PhD: A Combination Approach to ALS

September 07, 2020

The investigator at the Healey & AMG Center for ALS detailed the combination of AMX0035 and other agents and how ALSFRS-R scores translate to daily life.

Researchers Characterize Rare Form of Aggressive Alzheimer Disease

September 07, 2020

Researchers from Mayo Clinic reported characteristics of 55 patients with a newly defined form of Alzheimer disease with unusual or atypical symptoms.

Lacosamide Meets Primary End Point, Lemborexant Well-Tolerated in Elders, Cala Trio Reduces Hand Tremor

September 05, 2020

Neurology News Network for the week ending September 5, 2020.

NeurologyLive Friday 5 — September 4, 2020

September 04, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 4, 2020.

Pocket Card Algorithm May Help Improve Status Epilepticus Treatment

September 04, 2020

Multidisciplinary teams who had the pocket card available had shorter times to rescue therapy initiation and similar rates of adequate dosing.

Pitolisant Shows No Cardiac Safety Signals in Narcolepsy

September 04, 2020

Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.

Sucheta M. Joshi, MD: Challenges in Transitioning to Adult Epilepsy Care

September 04, 2020

The pediatric neurologist at Hurley Medical Center of the University of Michigan Hospitals-Michigan Medicine, detailed the challenges those with epilepsy face when transitioning to adult care.

Sabrina Paganoni, MD, PhD: Takeaways From the CENTAUR Trial of AMX0035

September 03, 2020

The investigator at the Healey & AMG Center for ALS spoke to the newly released findings of the phase 2/3 trial of the investigational combination ALS agent AMX0035.

CT Scans Linked to Increased Risk of Futile Recanalization in Stroke

September 03, 2020

The researchers noted that future studies should examine the cost-effectiveness of CT compared with MRI as the best initial imaging modality for mechanical thrombectomy.

Migraine History Linked to Recurrent Transient Global Amnesia

September 03, 2020

Findings suggest that compared with isolated cases, both earlier age at initial episode and a higher prevalence of personal and family history of migraine are linked to TGA recurrence.

Lara Jehi, MD: Raising Awareness of the Benefits of Epilepsy Surgery

September 03, 2020

The chief research officer and epilepsy specialist at Cleveland Clinic detailed the reasons why epilepsy surgery is not utilized as often as it should, and her efforts to raise awareness.

AMX0035 Slows Functional Decline in ALS in Phase 2/3

September 02, 2020

Data from the CENTAUR trial showed that the monthly rate of decline measured by ALSFR-S was 0.42 points slower for patients treated with the combination agent AMX0035.

Mary Schroth, MD: The Impact of FDA Approvals on SMA Advocacy

September 02, 2020

The chief medical officer at Cure SMA detailed the importance of having various treatment options for patients, particularly for adults with SMA.

Longitudinal Sleep Problems in Children Linked With Negative Well-Being

September 02, 2020

The findings support the integration of sleep assessments into routine developmental screenings in school and primary care settings.

Lacosamide Reduces Risk of Second Tonic-Clonic Seizure

September 02, 2020

The FDA-approved epilepsy monotherapy showed significant reductions in primary generalized tonic-clonic seizures of ≥50% and ≥75% from baseline.

Modified Atkins and Low Glycemic Index Diets Noninferior to Ketogenic Diet in Epilepsy

September 02, 2020

A low glycemic index therapy diet is associated with the least number of and least severe adverse events among all 3 epileptic diet methods, with similar reductions in seizure burden.

Solriamfetol Improves Excessive Daytime Sleepiness and Driving Performance Ability

September 01, 2020

The FDA-approved agent showed significant impact in decreasing standard deviation of lateral position, a measure used to assess driving performance.

Pitolisant Improves Daytime Sleepiness and Cataplexy in Severely Burdened Patients

September 01, 2020

Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.

Marwan Sabbagh, MD: Observations From AAIC 2020

September 01, 2020

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic detailed the state of Alzheimer disease and what research particularly grabbed his attention at AAIC 2020.

Lemborexant Demonstrates Efficacy in Elders

September 01, 2020

Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.

Mary Schroth, MD: Making Strides in Treating Spinal Muscular Atrophy

August 31, 2020

The chief medical officer at Cure SMA offers insight on the current SMA therapeutic landscape and what the organization is focused on going forward.

The Key Role of Biomarkers in Alzheimer Disease Research

August 31, 2020

In part 2 of this interview, Marwan Sabbagh, MD, provides insight on what he feels is the most promising field of research in Alzheimer disease right now.

Cala Trio Neuromodulation Device Effectively Reduces Symptoms in Essential Tremor

August 31, 2020

After wearing the noninvasive device, 62% of TETRAS-rated patients and 68% of BF-ADL-rated patients whose tremors were rated as "severe" or "moderate" improved to "mild" or "slight" scores.

Selective Inverse Agonists of the Histamine 3 Receptor as Treatment for Narcolepsy

August 29, 2020

Managing narcolepsy via behavioral strategies to improve excessive daytime sleepiness may be challenging but has shown some added efficacy when combined with pharmacological treatment for EDS.

Lara Jehi, MD: Evidence Abounds for the Benefits of Epilepsy Surgery

August 29, 2020

The chief research officer and epilepsy specialist at Cleveland Clinic detailed how recent study findings might impact the patient perspective on epilepsy surgery.

Closing the Treatment Gap in Progressive MS

August 29, 2020

New biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.

FDA Approves Ofatumumab, EVT Effective in Late Presenting Stroke, Rimegepant Safe With CGRP Antibodies

August 29, 2020

Neurology News Network for the week ending August 29, 2020.

NeurologyLive Friday 5 - August 28, 2020

August 28, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.

AMX0035 Takes Dual Approach to Dementia

August 28, 2020

With a positive track record in ALS, the investigational agent now sets its sights on the Alzheimer disease pipeline.

The Importance of Healthy Living in Patients With Narcolepsy

August 28, 2020

Healthy lifestyle choices are an integral part of disease management for patients with narcolepsy who face an increased prevalence of comorbid cardiovascular and metabolic conditions.

Episode 16: Personalizing Our Approach to Medication Adherence in Parkinson Disease

August 28, 2020

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Rajesh Pahwa, MD.

Lemborexant Improves Sleep Outcomes Following Placebo Randomization Switch

August 27, 2020

Benefit from lemborexant was evident after 1 month of switching from placebo to the active treatment and was sustained through the entirety of the 12-month trial.

Cognitive Behavioral Therapy for Insomnia Shows Multiple Benefits for Women

August 27, 2020

Multiple abstracts at SLEEP 2020 show CBT-I’s success in aiding women with insomnia, including those going through pregnancy, and those who are veterans both with and without PTSD.

Shai Efrati, MD: Inducing Stem Cell Proliferation With Hyperbaric Oxygen Therapy

August 27, 2020

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed how hyperbaric oxygen therapy is being used to attempt to improve the damage from neurodegeneration.

Unraveling Autoimmune Epilepsy

August 27, 2020

Could expanding insights into the pathophysiology of autoimmune epilepsy offer seizure-free hope for patients?

Telemedicine, Technology, and the Future of Alzheimer and Dementia Care

August 26, 2020

Howard Fillit, MD, founding executive director and chief science officer of the Alzheimer's Drug Discovery Foundation and clinical professor of geriatric medicine and palliative care, medicine, and neuroscience at Mount Sinai School of Medicine, detailed the role telemedicine plays in treating Alzheimer disease.

Soticlestat Meets Primary End Point in Dravet and Lennox-Gastaut Syndromes

August 26, 2020

The first-in-class CH24H inhibitor was associated with a reduction in seizures and seizure frequency in an early analysis of the phase 2 ELEKTRA study, with plans to initiate the move to phase 3 in Dravet syndrome.

Approaching Multiple Sclerosis With a Global Perspective

August 26, 2020

A group of international experts in the treatment of multiple sclerosis offer their varying viewpoints on the history, identification, and management of the disease.

Healthy Diet May Reduce Nonmotor Symptoms in Parkinson Disease

August 26, 2020

Increased consumption of vegetables, nuts, and moderate alcohol intake are each inversely associated with the odds of 3 or more prodromal features that precede Parkinson disease.

Marwan Sabbagh, MD: How Aducanumab Impacts Future Studies

August 26, 2020

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed how Alzheimer disease research may change if aducanumab becomes approved.

Motor, Non-Motor Symptoms Among Top Concern in Parkinson Disease

August 25, 2020

In part 2 of this interview, Hubert Fernandez, MD, director of the Center for Neurological Restoration at Cleveland Clinic, detailed the greatest unmet needs as well as the utility of deep brain stimulation in patients with Parkinson disease.

Pierrick Arnal, PhD: Conducting Sleep Studies With the Dreem Headband

August 25, 2020

The vice president of science and medical at Dreem offered his opinion on how the company’s headband device can improve how sleep studies are conducted.

Hearing Impairment May Serve as Preclinical Marker of Neurodegeneration

August 25, 2020

The authors noted that taken together, the findings suggest that either hearing impairment may affect brain atrophy and neuropathologic burden or that underlying pathologies may impair functional hearing abilities, even prior to dementia onset.

Early Intervention in SMA: How Access to Therapy Will Alter Disease Management As We Know It

August 25, 2020

Efforts to cut through regulatory red tape will help ensure earlier access to potentially lifesaving treatments.

Novel Seizure Subtype Identified With Video-EEG

August 24, 2020

The investgators noted that the absences before the tonic-clonic convulsions can be as short as 5 seconds, suggesting they may be more frequently occurring than those being observed or reported.

Neuroanatomical Biotypes Can Predict Parkinson Disease Progression

August 24, 2020

Recognition of the distinct neuroanatomical patterns, symptoms, and rates of progression within different biotypes can play a pivotal role in the implementation of precision medicine for Parkinson disease.

Jeffrey Cummings, MD, ScD: Repurposed Agents Within Alzheimer Disease Pipeline

August 24, 2020

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada-Las Vegas discussed the role repurposed agents play in Alzheimer disease development.

Alzheimer Disease May Influence Sleep Patterns

August 24, 2020

Researchers noted that further examinations are needed of the genetic heterogeneity depression syndromes to test for causal relationships between distinct subtypes of depression and Alzheimer disease.

Acute Migraine Agent Rimegepant Appears Safe With CGRP Monoclonal Antibodies

August 22, 2020

The data support and extend the safe use of combination treatment with rimegepant and CGRP monoclonal antibodies in migraine that was initially reported in 2 earlier cases.

Satralizumab Approved, Epilepsy Surgery Cost-Effective, FDA Approves DMD Treatment Viltolarsen

August 22, 2020

Neurology News Network for the week ending August 22, 2020.

NeurologyLive Friday 5 — August 21, 2020

August 21, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

Noninvasive Neuromodulation for Essential Tremor: An Important Tool for Maintaining Independence at Home

August 21, 2020

Noninvasive neuromodulation with TAPS is a safe and effective tool that offers particular utility in the age of COVID-19 when other treatment options may be less accessible.

Lara Jehi, MD: Pros and Cons of Epilepsy Surgery

August 21, 2020

The chief research officer and epilepsy specialist at Cleveland Clinic detailed the patient-centered pros and cons associated with epilepsy surgery, as well as the stigmas related to it.

Neurological Deterioration May Play a Factor in Stroke Outcome

August 21, 2020

Neurological deterioration was observed in about 1 of 7 patients who received in-hospital care for acute ischemic stroke or transient ischemic attack.

Ofatumumab FDA-Approved for Relapsing Multiple Sclerosis Treatment

August 20, 2020

Novartis’ anti-CD20 monoclonal antibody ofatumumab (Kesimpta) is administered once monthly at home, and is expected to be available for those with multiple sclerosis as early as September 2020.

Aducanumab: A Potentially Landscape-Altering Treatment for Alzheimer

August 20, 2020

Marwan Sabbagh, MD, director of the Lou Ruvo Center for Brain Health and a neurologist at Cleveland Clinic, detailed why aducanumab’s upcoming FDA decision bears immense weight for patients with Alzheimer disease and future clinical studies.

FDA Approves Qutenza for Treatment of Neuropathic Pain

August 20, 2020

Qutenza becomes the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy.

Sabrina Paganoni, MD, PhD: AMX0035 and the Future of ALS Care

August 20, 2020

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital offered her perspective on the expected developments for ALS care in next few years, and where AMX0035 might fit in that landscape.

Laryngeal Dysfunction May Distinguish Multiple System Atrophy From Parkinson Disease

August 19, 2020

The presence of laryngeal movement disorders—identified in 93% of the MSA group—may serve as a diagnostic biomarker of MSA independent of phenotype, disease duration, or patient age.

Parkinson Disease Positive Outlook Stems From Improvements in Research

August 19, 2020

Hubert Fernandez, MD, the director of the Center for Neurological Restoration at Cleveland Clinic, detailed the importance of raising awareness for Parkinson disease and the strides made in research.

Lara Jehi, MD: Cost-Effectiveness of Epilepsy Surgery

August 19, 2020

The chief research officer and epilepsy specialist at Cleveland Clinic detailed her most recent findings on the cost-effectiveness of epilepsy surgery for drug-resistant temporal lobe epilepsy.

Challenges, Biomarkers, and Combination Therapy: Alzheimer Research

August 19, 2020

The head of the Non-Invasive Brain Stimulation Lab at the Santa Lucia Foundation spoke to the challenges in Alzheimer research, biomarkers, and the next steps for rotigotine in this population.

EEG Shows Utility in Detecting Abnormalities in Prodromal Dementia With Lewy Bodies

August 18, 2020

Researchers noted that the development of a simple scale focused on abnormalities in dementia with Lewy bodies may help to further incorporate the EEG in clinical decision-making.

Meta-Analysis Suggests Delirium Is Associated With Long-Term Cognitive Decline

August 18, 2020

For both surgical and nonsurgical patients, delirium may play a role as an independent risk factor for long-term cognitive decline, implying that the reduction of the former may improve the latter.

Marwan Sabbagh, MD: Outlook of Aducanumab in Alzheimer Disease

August 18, 2020

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the potential of aducanumab and the amyloid theory in patients with Alzheimer disease.

EpiTRAQ Is a Reliable Tool for Helping Transition Epilepsy Patients to Adult Care

August 18, 2020

The goal is to improve the delivery of care and outcomes for patients with epilepsy as they transition from pediatric to adult care settings, where there is often less oversight.

Migraine Screening Is Not Common in Optometry Practice

August 17, 2020

A follow-up cohort study demonstrates that educating optometrists on the importance and utility of a validated migraine screening tool is a simple, low-time investment intervention, the researchers stated.

Pierrick Arnal, PhD: The Dreem Headband Versus Polysomnography

August 17, 2020

The vice president of science and medical at Dreem discussed how the company’s headband device stacked up against polysomnography for sleep monitoring.

Rotigotine Shows Phase 2 Promise for Dopaminergic Agonists in Alzheimer Disease

August 17, 2020

The head of the Non-Invasive Brain Stimulation Lab at the Santa Lucia Foundation discussed the phase 2 findings and offered takeaways on rotigotine’s possible place in Alzheimer treatment.

EVT Shows Benefit in Large Vessel Occlusion Stroke Despite Late Presentation

August 17, 2020

Endovascular treatment may benefit patients with emergent large vessel occlusion and target mismatch profiles regardless of the time from onset.

Satralizumab Approved for Treatment of Neuromyelitis Optica Spectrum Disorder

August 15, 2020

The subcutaneous injection is indicated in patients with anti-aquaporin-4 antibody positive NMOSD.

Epilepsy Surgery Is Cost Effective for Refractory Temporal Lobe Epilepsy

August 15, 2020

Patients with refractory temporal lobe epilepsy may be more inclined to opt for surgery when they understand the long-term cost effectiveness, as well as rates of increased seizure freedom and reduced seizure relapses.

Aducanumab BLA Accepted, Risdiplam Receives FDA Approval, Ofatumumab Lower ARRs Than Teriflunomide

August 15, 2020

Neurology News Network for the week ending August 15, 2020.

NeurologyLive Friday 5 — August 14, 2020

August 14, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

Aducanumab's Unlikely Road to the FDA: Is Approval Imminent?

August 14, 2020

Recent news that the FDA has granted the fastest possible review for Biogen’s Alzheimer disease treatment aducanumab may be indicative of the agency’s increasing confidence in the drug.

Hubert Fernandez, MD: The Top Concerns for Parkinson Disease

August 14, 2020

The director of the Center for Neurological Restoration at Cleveland Clinic describes the greatest unmet needs in Parkinson disease research.

Episode 15: The Latest Developments in the SMA Treatment Landscape

August 14, 2020

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Richard Finkel, MD.

Pierrick Arnal, PhD: The Development and Utility of the Dreem Headband

August 13, 2020

The vice president of science and medical at Dreem offered an overview of the hardware that makes up the Dreem Headband and how it was developed to monitor sleep.

Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers

August 13, 2020

Advocacy organization Cure SMA provides guidance for health care providers caring for patients with SMA during the ongoing COVID-19 pandemic.

Regenerating Tissue to Target Disease Pathophysiology With Hyperbaric Oxygen Therapy

August 13, 2020

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center explained his research with hyperbaric oxygen therapy and explored the potential it may hold as a regenerative treatment.

Community-Based Study Confirms REM Sleep Behavior Disorder Risk Factors

August 13, 2020

Notably, the data unveiled a previously unreported link between a positive family history of parkinsonism and dementia, and carbon monoxide poisoning.

Viltolarsen Approved for Duchenne Muscular Dystrophy Treatment

August 13, 2020

The drug is indicated in patients with a confirmed mutation in the DMD gene that is amenable to exon 53 skipping.

Personal Social Networks Associated With Physical Function in Multiple Sclerosis

August 12, 2020

Larger social network effective size correlated with better physical function, while network constraint correlated with worse physical function in those with multiple sclerosis.

GammaCore nVNS Device Offers Versatile Option in Migraine and Cluster Headache

August 12, 2020

A review of clinical literature and evidence suggests that the gammaCore device (electroCore) is safe and effective in the treatment of cluster headache and migraine, and carries potential to treat more.

Katrina Celis, MD: Genetics and Their Role in Alzheimer Research, Clinical Care

August 12, 2020

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed the role that increased APOE ε4 expression can have on future research and clinical care.

Could Hyperbaric Oxygen Therapy Improve Cognitive Function in Dementia?

August 12, 2020

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center offers insight into the attempt to regenerate injured tissue in the brain as a way to potentially treat Alzheimer disease and dementia.

Sabrina Paganoni, MD, PhD: AMX0035 Phase 2 Performance in ALS

August 11, 2020

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital spoke to findings of the phase 2 CENTAUR trial of AMX0035 in amyotrophic lateral sclerosis.

FDA Accepts BLA for Pegunigalsidase Alfa for Fabry Disease

August 11, 2020

After receiving fast track designation by the FDA in January 2018, pegunigalsidase alfa now has a PDUFA date scheduled for January 27, 2021.

Sustained Immunotherapy May Improve Secondary Progressive MS Disability Outcomes

August 11, 2020

A cohort study showed that those with relapse activity who received DMTs accounted for a greater percent of time with a reduced Multiple Sclerosis Severity Score progression slope during SPMS.

Peter McAllister, MD: JUNIPER Trial on DaxibotulinumtoxinA for Spasticity

August 11, 2020

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research detailed the end points and long-term goals of the phase 2 JUNIPER upper limb spasticity trial.

Vitamin D and Calcium Supplementation Reduces Recurrences of Vertigo

August 11, 2020

Trial data suggest that management of vitamin D deficiency should be considered in patients with frequent attacks of benign paroxysmal positional vertigo.

Hypertension Is Significantly Undertreated in Those With History of Stroke

August 10, 2020

Future studies are needed to determine the preferential antihypertensive medication in patients after experiencing a stroke, despite the results suggesting a gap in secondary prevention of stroke.

Ofatumumab Superior to Teriflunomide in ARR Reduction for Multiple Sclerosis

August 10, 2020

The full data from the ASCLEPIOS I and II trials suggest that the Novartis agent ofatumumab is superior to teriflunomide in reducing annualized relapse rates and other measurements of disease progression in MS.

Routine EEG May Be Alternative to Continuous EEG When Resources are Limited

August 10, 2020

Future studies may validate the use of routine electroencephalogram as an alternative to continuous electroencephalogram in centers with limited resources, as despite better seizure detection with continuous monitoring, outcomes were similar between the methods.

Jeffrey Cummings, MD, ScD: Greatest Unmet Needs in Alzheimer Disease

August 08, 2020

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada–Las Vegas discussed the leading challenges for those with Alzheimer disease.

Rare Neurologic Disease Pipeline Bolstered in Recent Weeks

August 08, 2020

Adding to a flurry of pipeline movement since July, 2 more rare disease agents—VTA-110 for DMD and arimoclomol for NPC—have made positive steps in their clinical development recently.

Risdiplam Approved as First Oral Treatment for SMA

August 07, 2020

The agent, marketed under the brand name Evrysdi, is the first at-home therapy indicated for treatment of adults and children with SMA.

NeurologyLive Friday 5 — August 7, 2020

August 07, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 7, 2020.

Addressing Photophobia in the Headache Clinic

August 07, 2020

Kathleen Digre, MD, past president of the American Headache Society, discusses the barriers to correct identification and treatment of eye symptoms in people with migraine.

Hubert Fernandez, MD: Therapeutic Innovations For Parkinson Disease

August 07, 2020

The director of the Center for Neurological Restoration at Cleveland Clinic detailed the recent technological and therapeutic innovations and their advantages in treating Parkinson disease.

FDA Accepts Aducanumab for Review as Alzheimer Disease Treatment

August 07, 2020

A PDUFA date has been scheduled for March 7, 2021, but the agency said it would consider an even more expedited review if warranted.

Ganaxolone Receives Rare Pediatric Disease Designation for CDD

August 07, 2020

Marinus Pharmaceuticals, the agent’s manufacturer, plans to announce topline data from the phase 3 Marigold study in the third quarter of this year.

Q&A: Genetic Ancestry and Alzheimer Disease Risk

August 06, 2020

Katrina Celis, MD, a postdoctoral fellow at the University of Miami Miller School of Medicine, discussed how ancestral genetics can play a key role in Alzheimer disease risk.

Sargramostim Shows Safety and Promise as Potential Alzheimer Treatment

August 06, 2020

The investigators wrote that the Alzheimer’s Association “Part the Cloud” funded 24-week treatment trial is now warranted after sargramostim showed a safe and tolerable profile.

AHA Announces Funding for New Center for Brain Health and Dementia at Boston University

August 06, 2020

Through a joint initiative with Bill Gates, a $3.3 million funding influx will go toward the Strategically Focused Research Network on Health Technologies and Innovation program’s fifth network center.

Shai Efrati, MD: Progression of Hyperbaric Oxygen Therapy for Neurodegeneration

August 06, 2020

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed the history of the research and offered insight into the attempt to regenerate injured tissue in the brain.

Sabrina Paganoni, MD, PhD: Collaboration in the CENTAUR Trial of AMX0035 in ALS

August 05, 2020

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital spoke to the need for more collaborative efforts in ALS research.

Dementia-Related Psychosis Places Heavy Burden on Patients and Caretakers

August 05, 2020

Data from 2 posters presented at AAIC 2020 suggest that there is an unmet need for safe and effective treatments for patients who experience dementia-related psychosis.

Raymond S. Turner, MD, PhD: Safety Results for Nilotinib in Alzheimer

August 05, 2020

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.

Tweet Chat Highlights: Mental Health in Neurology

August 05, 2020

An overview of the tweet chat on mental health in neurological disorders, featuring highlighted contributions from the medical community.

Plasma Replacement Shows Success in Mild to Moderate Alzheimer Disease

August 04, 2020

The findings suggest that plasma exchange has the potential to offer patients with Alzheimer disease a new modality of treatment, though additional studies are needed to further investigate the current areas of uncertainty.

FDA Approves Neuroform Stent System for Posterior Aneurysms

August 04, 2020

Results from the ATLAS Posterior PMA trial demonstrated that physicians can now address the more difficult posterior circulation aneurysms, offering hope for better outcomes in that patient population.

12 Modifiable Risk Factors to Reduce Dementia Risk

August 03, 2020

Excessive alcohol intake, head injury, and air pollution are among the newest dementia risk factors added to the Lancet Commission report.

FDA Approves Cannabidiol for Tuberous Sclerosis Complex

August 03, 2020

The approval also expands the age range of all Epidiolex indications to include patients age 1 and older.

Responsive Neurostimulation System Dramatically Reduces Seizures in Refractory Epilepsy

August 03, 2020

NeuroPace’s FDA-approved neurostimulation device helped 35% of patients with epilepsy achieve ≥90% reduction in seizure frequency, with 18% of patients reporting seizure freedom at last follow-up.

Nilotinib Safety Profile Sets Agent Up For Phase 3 Study

August 01, 2020

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.

Katrina Celis, MD: Ancestral Genetics and the Impact on Alzheimer Disease Risk

August 01, 2020

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed her study presented at AAIC 2020 that examined Alzheimer risk associated with APOE ε4 in different genetic populations.

Vaccinations Reduce Alzheimer Risk, FDA Approves Patient Controller App, Pimavanserin sNDA Accepted

August 01, 2020

Neurology News Network for the week ending August 1, 2020.

NeurologyLive Friday 5 — July 31, 2020

July 31, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.

Atogepant Reduces Monthly Episodic Migraine Days in Phase 3

July 31, 2020

The gepant agent significantly reduced mean monthly migraine days across all 3 doses—10 mg, 30 mg, and 60 mg—compared with placebo over the 12-week treatment period.

Episode 14: Trends in the Alzheimer Clinical Pipeline

July 31, 2020

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jeffrey Cummings, MD, ScD.

Hypertension, Diabetes, High BMI All Early Life Risk Factors for Dementia

July 30, 2020

Multiple studies presented at AAIC 2020 highlight and confirm previous hypotheses of the role that early life cardiovascular risk factors play for individuals who develop late life dementia.

Sabrina Paganoni, MD, PhD: AMX0035 and the Current ALS Treatment Landscape

July 30, 2020

The co-director of the Neurological Clinical Research Institute at Massachusetts General Hospital discussed how the investigational agent might fit into the landscape of amyotrophic lateral sclerosis treatment as it progresses through the pipeline.

VU319 Shows Safe Profile and Potential as M1 Allosteric Modulator for MCI

July 30, 2020

The data suggests that a planned multiple ascending dose study and a phase 2a proof-of-concept study in patients with mild cognitive impairment could be on the way.

CMSC Announces a Virtual Summer Celebration on August 3rd

July 30, 2020

The program will include video presentations of the Platform Abstracts covering the latest MS research as well as a CMSC Business Meeting with the winners of the International Journal of MS named.

Nilotinib Has Safe and Tolerable Profile in Alzheimer Disease

July 29, 2020

Results presented virtually at AAIC 2020 support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.

Candesartan Shows Signs of Neuroprotection in Older Adults With MCI and Hypertension

July 29, 2020

Compared to treatment with lisinopril, those treated with the angiotensin receptor blocker candesartan showed improvements on the Trial Making Test part A and B and Hopkins Verbal Learning Test-Revised delayed recall.

Hubert Fernandez, MD: Focus of Parkinson Disease Research

July 29, 2020

The director of the Center for Neurological Restoration at Cleveland Clinic details the direction of clinical research for Parkinson disease and efforts that are being made to alleviate quality of life issues for those with the disease.

Pimavanserin Reduces Dementia-Related Psychosis Symptoms

July 29, 2020

Additional data presented at AAIC 2020 shows the clinical benefit pimavanserin has on dementia-related psychosis while the agent awaits a PDUFA date of April 3, 2021.

Jeffrey Cummings, MD, ScD: Where Aducanumab Stands in Alzheimer Clinical Pipeline

July 29, 2020

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada­–Las Vegas gives his thoughts on the latest aducanumab update and its potential as a treatment for Alzheimer disease.

Rotigotine Shows Success in Symptomatic Treating of Mild to Moderate Alzheimer

July 29, 2020

Despite a lack of effect on memory and other cognitive tasks, as measured by ADAS-Cog-11, rotigotine improved frontal cognitive function and activities of daily living in those with Alzheimer.

P-Tau217 May Detect Alzheimer Disease, Brain Amyloidosis, Tauopathy

July 28, 2020

The performance of p-tau217 was similar to significantly more costly methods, such as PET imaging and measuring cerebrospinal fluid biomarkers.

Peter McAllister, MD: Lack of Treatment For Post-Stroke Spasticity

July 28, 2020

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research detailed the lack awareness and options for those who suffer from upper limb spasticity following a stroke.

Ped-MSSS May Serve as Alternative to EDSS in Pediatric-Onset MS

July 28, 2020

The findings indicate that the use of a MS severity score (Ped-MSSS) model may provide an alternative to EDSS scoring, which has been shown to be lower in pediatric disease, in clinical assessment of disease severity and disability accrual.

Jeffrey Cohen, MD: The Advantages of More Selective S1P Modulators

July 27, 2020

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the benefit that physicians and patients can be provided by highly selective S1P modulators in MS treatment.

Influenza, Pneumonia Vaccination May Reduce Alzheimer Disease Risk

July 27, 2020

A trio of studies presented at AAIC 2020 suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.

DaxibotulinumtoxinA Aims to Be Next Big Post-Stroke Spasticity Treatment

July 27, 2020

The medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research discussed the recent phase 2 JUNIPER upper limb spasticity trial of daxibotulinumtoxinA for injection.

Tweet Chat on Mental Health in Neurology Scheduled for July 29, 2020

July 27, 2020

Join NeurologyLive and the Women Neurologist Group on Twitter to discuss the importance of mental health and wellness in neurologic disorders.

FDA Approves App for Personalized Neuromodulation Control

July 25, 2020

The Patient Controller app will be made available in the coming weeks, according to designer Abbott.

Naeem Khan, MD: Ticagrelor Shines in Phase 3 THALES Trial

July 25, 2020

The vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases Portfolio detailed the results from the phase 3 THALES trial, and where ticagrelor stands among other FDA approved stroke treatments.

FDA Approves Xywav, Amantadine Reduces Daily "off" Time, Ticagrelor Lowers Risk of Composite of Stroke

July 25, 2020

Neurology News Network for the week ending July 25, 2020.

NeurologyLive Friday 5 — July 24, 2020

July 24, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 24, 2020.

Jeffrey Cummings, MD, ScD: Trends in the Alzheimer Disease Clinical Pipeline

July 24, 2020

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada-Las Vegas, details trends in Alzheimer disease research over the past few years.

Biogen Announces Phase 4 Study of SMA Therapy Nusinersen

July 24, 2020

The RESPOND study steering committee member and pediatric neuromuscular neurologist at Children’s Hospital of The King’s Daughters discussed the goals of the phase 4 trial of nusinersen in SMA.

Eyiyemisi Damisah, MD: Additional Insights Into Cell Death

July 24, 2020

The assistant professor of neurosurgery at Yale School of Medicine discussed what doors have been opened by a recent study of the cell death process she and colleagues conducted.

Ozanimod Linked to Improvements in Information Processing Speed

July 24, 2020

Data demonstrate a long-term, positive effect of the drug on cognitive function in patients with multiple sclerosis.

Older Age Is Associated With Worse Clinical Outcomes Post-Stroke Following EVT

July 23, 2020

The study authors noted that clinicians should consider the data when recommending endovascular treatment for older adults.

Advancing the Ticagrelor Pipeline in Stroke

July 23, 2020

In part 2 of this interview, the vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases portfolio discusses future trials with ticagrelor and when they anticipate a possible FDA approval.

Jeffrey Cohen, MD: S1P Modulator Development in Multiple Sclerosis

July 23, 2020

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the development of the sphingosine-1-phosphate modulator class in MS treatment.

FDA Accepts sNDA for Pimavanserin for Dementia-Related Psychosis

July 23, 2020

The regulatory agency has set prescription drug user fee act action date of April 3, 2021, for the Acadia Pharmaceuticals product.

Hubert Fernandez, MD: Raising Awareness For Parkinson Disease on World Brain Day

July 22, 2020

The director of the Center for Neurological Restoration at Cleveland Clinic discussed the importance of raising awareness of Parkinson disease on World Brain Day, highlighting the magnitude of the disease.

FDA Approves JZP-258 for Cataplexy and Daytime Sleepiness

July 22, 2020

The treatment, marketed as Xywav, becomes the first treatment indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in 15 years.

Alzheimer Disease Treatment Pipeline: Hope is Trending

July 22, 2020

As of February of this year, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.

World Brain Day: Hot Topics in Parkinson Disease

July 22, 2020

This year, the World Federation of Neurology partnered with the International Parkinson and Movement Disorder Society to spotlight advancements in Parkinson disease.

THALES Ticagrelor Trial Promising for Preventing Recurrent Stroke

July 22, 2020

The vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases portfolio discussed the findings of the THALES trial, and how ticagrelor stands alone among stroke treatments.

Dreem Headband EEG Device Accurately Monitors Sleep, Processes Sleep Stages

July 21, 2020

The affordable device’s accuracy compared to polysomnography may pave the way for a better way to conduct larger scale, longitudinal sleep studies.

Amantadine Reduces Off Time, Disruptive Motor States in Parkinson Disease

July 21, 2020

The FDA-approved medication showed a robust ability to decrease hours spent “on” with troublesome dyskinesia in patients with Parkinson disease.

Matthew Robbins, MD: Headaches Associated With COVID-19

July 21, 2020

The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.

Remote Electrical Neuromodulation Proves Effective in Chronic Migraine

July 20, 2020

REN may offer a novel alternative for current pharmacological and non-pharmacological treatments in chronic migraine that combines efficient treatment with minimal adverse effects.

Antisense Oligonucleotide Tofersen Gains Steam With Positive Phase 1/2 Results

July 20, 2020

The vice president and head of the Neuromuscular Development Unit at Biogen, and study coauthor, discussed the implications of recently published data on tofersen and the ongoing work in phase 3.

Higher Rates of Stroke Observed With COVID-19 Than Influenza

July 20, 2020

While further study is required, the data support vigilance of the symptoms and signs of acute ischemic stroke in patients with COVID-19 to reduce the burden of long-term disability.

Tofersen Shows Positive Signs in SOD1-Targeted Treatment of ALS

July 19, 2020

The vice president and head of the Neuromuscular Development Unit at Biogen, and study coauthor, offered insight into the findings of a phase 1/2 trial of the SOD1-targeted antisense oligonucleotide.

Aldesleukin Granted Orphan Drug Designation for ALS

July 18, 2020

The Clinigen Group’s ALS treatment is currently being investigated in a phase 2 trial that is expected to conclude in September 2021.

sNDA Granted to Ticagrelor, BAN2401 Phase 3 Trial Launched, Telemedicine Reimbursement Set to Expire

July 18, 2020

Neurology News Network for the week ending July 18, 2020.

sNDA Granted to Ticagrelor, BAN2401 Phase 3 Trial Launched, Telemedicine Reimbursement Set to Expire

July 18, 2020

Neurology News Network for the week ending July 18, 2020.

NeurologyLive Friday 5 — July 17, 2020

July 17, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 17, 2020.

First Dataset on Parkinson Disease and COVID-19 Released

July 17, 2020

Data from the Michael J. Fox Foundation’s Fox Insight study reveal a number of consequences as a result of the virus for those with chronic neurologic diseases.

Eyiyemisi Damisah, MD: Understanding Aging and Cell Death

July 17, 2020

The assistant professor of neurosurgery at Yale School of Medicine discussed the work that still needs to be done to understand the role cell death process might play in neurodegeneration as the human body ages.

Episode 13: Sequencing SNPs in Huntington Disease

July 17, 2020

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Claassen, MD, MS.

Ticagrelor With Aspirin Reduces Rate of Composite of Stroke and Death

July 17, 2020

In addition to showing significant and clinically meaningful reduction in acute ischemic stroke and transient ischemic attack, ticagrelor showed a consistent safety profile to what has been observed in previous trials.

Less REM Sleep Associated With Higher Mortality Risk in Older Adults

July 16, 2020

A cross-sectional analysis of 2 study cohorts suggests that less rapid eye movement sleep is linked with an increased risk of all-cause mortality, which persisted across different causes of death.

Eyiyemisi Damisah, MD: The Relationship Between Microglia and Astrocytes

July 16, 2020

The assistant professor of neurosurgery at Yale School of Medicine discussed the observations she and colleagues have made of the relationship between microglia and astrocytes in the cell death process.

Moderna COVID-19 Vaccine Shows Promise, Moves to Phase 3

July 16, 2020

The findings support the advancement of a 100-mcg dose vaccine to a phase 3 trial assessment in later summer 2020, while a phase 2 trial of a pair of different doses continues among 600 healthy adults.

Novel Radiotracer May Serve as Valuable Diagnostic Biomarker For Supranuclear Palsy

July 15, 2020

The 18F-PI-2620 radiotracer’s positive effect on diagnosing and differentiating patients with suspected progressive supranuclear palsy leaves questions about its potential as a PSP progression biomarker.

Phase 3 Study of BAN2401 in Preclinical Alzheimer Disease Announced

July 15, 2020

The investigational Alzheimer disease agent BAN2401 will be assessed in 1400 participants who will be randomized to either the A3 trial or the A45 trial.

Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination Treatment

July 15, 2020

The internal medicine resident physician at Montefiore Health System provided an overview of the study he and colleagues conducted on patients using onabotulinumtoxinA and CGRP agents in tandem.

AbobotulinumtoxinA Label Expanded to Include Upper, Lower Limb Spasticity Caused By Cerebral Palsy

July 15, 2020

Previous exclusions limiting use of the drug in spasticity caused by cerebral palsy have been lifted.

Eyiyemisi Damisah, MD: The Cell Death Processes in the Brain

July 14, 2020

The assistant professor of neurosurgery at Yale School of Medicine discussed the current understanding of the process of cell death in the brain, and what players are involved in the removal of dead cells.

COVID-19-Associated Ischemic Strokes Are More Severe, Study Suggests

July 14, 2020

The findings are particularly relevant for prehospital stroke awareness and improvement of in-hospital acute stroke protocols.

Bruce Cree, MD, PhD, MAS: The Future Landscape in NMOSD

July 14, 2020

The clinical research director at the UCSF Multiple Sclerosis Center discussed potential future assessments of inebilizumab (Uplizna; Viela Bio) and the agents still in development for NMOSD.

Normalized Space and Time Improves Post-Operative Outcome Prediction in Epilepsy

July 14, 2020

A retrospective analysis suggests that normalizing the spatial proximity between nearby electrodes and more extensive electrode coverage improved the accuracy of post-surgery seizure outcomes.

Kathleen Digre, MD, on Eye Pain and Photophobia in Migraine

July 14, 2020

Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic.

Video Game Intervention Improves Processing Speed in Multiple Sclerosis

July 13, 2020

Low-risk, digital video game interventions could represent a clinically valuable approach to improving processing speed in adults with multiple sclerosis.

Eyiyemisi Damisah, MD: The Role of Astrocytes and Microglia in Cell Death

July 13, 2020

The assistant professor of neurosurgery at Yale School of Medicine spoke to the observations she and colleagues made to better understand the process of cell death and corpse removal in the brain.

Central Vein Sign: Redefining MS Diagnostic Criteria

July 13, 2020

In part 2 of this interview, Daniel Ontaneda, MD, PhD, the co-principal investigator of the CAVS-MS study, describes the long-term goals of the study and how the central vein sign will be incorporated into standard diagnostic criteria for multiple sclerosis.

Miller School Plays Pivotal Role in Securing National Alzheimer's Disease Research Center

July 13, 2020

The University of Miami Miller School of Medicine designated as 1 of the 31 centers of excellence by the National Institute of Aging and will play a huge role in the 1Florida Alzheimer's Disease Research Center.

Total Migraine Pain Burden Reduced With Galcanezumab in Post-Hoc Analysis

July 13, 2020

Treatment with galcanezumab (Emgality; Eli Lilly) was associated with improvements in total pain burden for patients with both chronic and episodic migraine compared to placebo groups.

Natalizumab Improves Disability in Relapsing-Remitting Multiple Sclerosis

July 11, 2020

Treatment with natalizumab helps both confirmed disability and functional system, suggesting it may be considered when evaluating treatment options for those with relapsing-remitting multiple sclerosis.

Aducanumab BLA Submitted, Daridorexant Shows Phase 3 Efficacy, Neurologic Symptoms in Children With COVID-19

July 11, 2020

Neurology News Network for the week ending July 11, 2020.

NeurologyLive Friday 5 — July 10, 2020

July 10, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 10, 2020.

Thank You for a Wonderful 2020 Virtual SMA Conference!

July 10, 2020

Cure SMA gives an overview of the recent 2020 Virtual SMA Conference, with highlights on new data and poster sessions.

Cure SMA Publishes Article on SMA Clinical Trial Readiness Program

July 10, 2020

The latest program from Cure SMA aims to better understand the capacity of spinal muscular atrophy centers in the US and to continue to carry out effective clinical trials.

Daniel Claassen, MD, MS: Takeaways from SNP Research in Huntington Disease

July 10, 2020

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on the feasibility of genotyping, phasing, and targeting of SNPs in Huntington disease.

Ticagrelor Granted Priority Review for Reduction of Subsequent Stroke

July 10, 2020

The FDA has set the Prescription Drug User Fee Act action date for Q4 2020 for the AstraZeneca agent.

Tofersen Reduces SOD1 CSF Concentrations in Patients With ALS

July 10, 2020

In the phase 1/2 study, the Biogen agent showed a favorable reduction of SOD1 concentrations compared to placebo, particularly with the 100-mg dose, and is being assessed in an ongoing phase 3 study, VALOR.

Neurology Groups Come Together to Support Continued Telemedicine Service, Payment Parity

July 09, 2020

Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.

Matthew Robbins, MD: Residency During COVID-19

July 09, 2020

The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.

Reduced Circadian Rhythmicity Associated With Increased Risk of Parkinson Disease

July 09, 2020

Reduced amplitude and/or robustness of the rhythms, rather than disrupted timing, are the most indicative of a subsequent risk of PD, independent of nighttime sleep disturbances.

NIH Announces ALS Innovative Research Initiative

July 09, 2020

The National Institutes of Health program, dubbed Accelerating Leading-edge Science in ALS, or ALS2, is set to invest $25M over 5 years for exceptionally creative and riskier research.

Daniel Claassen, MD, MS: Selective Knock-Downs in Huntington Disease

July 08, 2020

The associate professor of neurology at Vanderbilt University Medical Center spoke to the findings of a recent study in Huntington disease that assessed the feasibility of selectively knocking down mutant protein expression.

Inner Retinal Layer Thinning May Predict Multiple Sclerosis Conversion

July 08, 2020

New data suggest that peripapillary retinal nerve fiber layer thinning may be an independent and novel risk factor for conversion to multiple sclerosis in those with RIS.

Biogen Files Aducanumab BLA for Alzheimer Disease

July 08, 2020

Biogen’s biologics license application for aducanumab is supported by the phase 3 EMERGE and ENGAGE trials. The company has also requested a priority review designation.

Stopping Cannabis Use in Multiple Sclerosis May Improve Depression

July 08, 2020

Findings of the study provide a cautionary note in relation to cannabis use in people with MS, at least with respect to depression.

Vaccine-Proximate Febrile Seizures Not Linked to Developmental Problems

July 07, 2020

The lack of effect on cognitive function provides reassurance to clinicians and parents for the developmental outcomes of a well-recognized, albeit relatively uncommon, adverse event after immunization.

Chia-Chun Chiang, MD: Collecting Real-World Data Following FDA Approvals

July 07, 2020

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.

Long-Term Safety Study Confirms Efficacy of ADAM Zolmitriptan in Acute Migraine

July 07, 2020

The FDA accepted an NDA for Zosano’s ADAM zolmitriptan (Qytripta) in the acute treatment of migraine in early March, with a PDUFA date set for mid-October 2020.

Daniel Claassen, MD, MS: Allele-Selective Therapy for Huntington Disease

July 07, 2020

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on his and colleagues’ study of single nucleotide polymorphisms in Huntington disease.

COVID-19 Linked to Potential New Neurologic Symptoms in Children

July 07, 2020

One of the first case-series studies that analyzed children with COVID-19 suggest that SARS-CoV-2 should be considered for differential diagnosis in children presenting with new neurologic symptoms and splenium signal changes on MRI.

Insomnia Treatment Daridorexant Builds Momentum With Confirmatory Phase 3 Results

July 06, 2020

The dual orexin receptor antagonist improved sleep maintenance and total sleep time without residual next-day effects.

Early-Life Cognitive Enrichment Leads to Better Late-Life Cognitive Health

July 06, 2020

New findings indicate that cognitive health in old age depends in part on cognitive development in early life.

Exploring the Burden of Cerebrovascular Disease in Virginia

July 06, 2020

Located in the “Stroke Belt” of the US, Virginia presents a unique perspective on the interplay of social, ethnic, and cultural implications on population health.

Central Vein Sign: A Biomarker to Alleviate MS Misdiagnosis

July 05, 2020

In part 1 of this interview, Daniel Ontaneda, MD, PhD, the co-principal of the CAVS-MS study, outlines the reasons for why the central vein sign can lower rates of misdiagnosing multiple sclerosis.

Eight Ways to Evaluate a Telehealth Vendor

July 04, 2020

A look at the questions you should be asking during the decision-making process of picking a telehealth vendor.

NeurologyLive Friday 5 — July 3, 2020

July 03, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.

Stroke-Inducing Cavernous Angiomas Linked to Gut Microbiome

July 03, 2020

An NIH-funded study provided supporting evidence of an association between high levels of gram-negative bacteria and a stroke-, seizure-, and headache-inducing vascular abnormality.

Adapting Neurological Care Amid COVID-19

July 03, 2020

In the wake of the COVID-19 pandemic, health care providers and patients have had to quickly adapt to new formats of care models to promote safety while retaining care standards.

Could Combination OnabotulinutoxinA and CGRP Agents Be Safe and Effective?

July 02, 2020

Fred Cohen, MD, offers insight on his study exploring the utility of combined Botox with anti-CGRP preventives for patients with chronic migraine.

Stroke Care Evolves During These Uncertain Times

July 02, 2020

Andrew Russman, DO, guest editor for NeurologyLive, provides insight on how stroke care has changed during the COVID-19 pandemic.

Deep Brain Stimulation for Essential Tremor May Induce Dysphagia

July 02, 2020

During DBS stimulation “on” periods, all patients experienced varying degrees of dysphagia, with significant improvements when stimulation was “off.”

Verdiperstat Aims to Be First DMT for Multiple System Atrophy

July 01, 2020

Biohaven’s verdiperstat has entered a phase 3 trial for the treatment of multiple system atrophy, with a new drug application submission on the agenda for late 2021.

Short-Term Dosing Regimen Gives Cladribine an Advantage in MS

July 01, 2020

Kottil Rammohan, MD, director of the MS Division and Multiple Sclerosis Center of Excellence at the University of Miami, discussed the EMD Serono agent’s history and advantages for the patient community.

Severe COVID-19 in Multiple Sclerosis Linked to Disability Status, Age, Obesity

July 01, 2020

Notably, the cohort assessment did not identify a link between exposure to disease-modifying therapies and COVID-19 severity.

Intranasal Insulin Has No Functional, Cognitive Benefits in Alzheimer Disease

June 30, 2020

No differences were observed between the insulin and placebo groups on several clinical outcome measures as well as biomarker evaluations.

Targeting Bruton Tyrosine Kinase for Multiple Sclerosis Treatment

June 30, 2020

An in-depth look into the expanding landscape of multiple sclerosis treatments that target bruton tyrosine kinase.

Alzheimer Disease Biomarkers Follow Predictable Order in Down Syndrome

June 30, 2020

People with Down syndrome may be a suitable population for clinical trials for Alzheimer disease as prevalence ranges from 90% to 100% by the seventh decade of life.

Managing Narcolepsy and Excessive Daytime Sleepiness

June 29, 2020

In this Peer Exchange, sleep experts provide insight into the latest narcolepsy treatments and areas that require further research.

OnabotulinumtoxinA sBLA Accepted for Detrusor Overactivity Due to Neurologic Conditions

June 29, 2020

The sBLA for onabotulinumtoxinA is supported by the findings from a randomized, double-blind phase 3 study evaluating the safety and efficacy of onabotulinumtoxinA in more than 100 pediatric patients.

Internet-Delivered Insomnia Intervention Effective in Young Adult Cancer Survivors

June 29, 2020

Cancer centers providing care for adolescent and young adult cancer survivors may consider committing resources to routinely screen for sleep disorders and to support patient access to evidence-based insomnia treatment.

Telemedicine in Dementia Care: Here to Stay?

June 27, 2020

In part 2 of this interview, the associate director of the Center for the Aging Brain at Montefiore Medical Center anticipates life with telemedicine after the pandemic and describes the at-home advantage it gives clinicians.

Chia-Chun Chiang, MD: Variations in FDA Approved Migraine Medications

June 27, 2020

The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.

NeurologyLive Friday 5 — June 26, 2020

June 26, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.

Comorbidities Influence Clinical Outcomes in Multiple Sclerosis

June 26, 2020

Worsened clinical outcomes for patients with MS due to an increase in comorbidities could provoke the need of greater management of them in the clinical care setting.

Episode 12: Masculinity and Multiple Sclerosis

June 26, 2020

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Bryan Davis, PsyD, MS.

FDA Approves Fenfluramine for Treatment of Dravet Syndrome

June 26, 2020

Fintepla, marketed by Zogenix, will be available for prescription for the rare pediatric epilepsy syndrome beginning in July 2020 through a REMS program.

Treating Medication Overuse Headache: Opportunities for Improvement

June 25, 2020

A whole-patient approach to management, coupled with new, more targeted treatments, may help reduce the incidence of medication overuse headache.

Percept PC Deep Brain Stimulation System Gets Go-Ahead

June 25, 2020

The Medtronic device is the only DBS system that is eligible to be used for both 3T and 1.5T full-body MRI scans, with the first implant procedure scheduled at Mayo Clinic.

EEG Abnormalities in Acutely Ill Patients With COVID-19

June 25, 2020

Preliminary findings from a retrospective sample series in the Bronx, New York.

Adapting Telemedicine for Dementia During COVID-19

June 25, 2020

In part 1 of this interview, the associate director of the Center for the Aging Brain at Montefiore Medical Center discussed how she adapted quickly to optimizing telemedicine for elderly patients with Alzheimer disease and cognitive decline.

Daniel Ontaneda, MD, PhD: Central Vein Sign as Potential Multiple Sclerosis Biomarker

June 25, 2020

The neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis and co-principal investigator of the CAVS-MS study details the specific reasons for examining central vein sign as a biomarker.

ReStore Exo-Suit Proves Reliable for Post-Stroke Gait Rehabilitation

June 24, 2020

The findings advance the translation of soft robotic exo-suits from the laboratory to the clinic and may motivate future controlled efficacy trials.

Bruce Cree, MD, PhD, MAS: Insights From the N-Momentum Study of Inebilizumab

June 24, 2020

The clinical research director at the UCSF Multiple Sclerosis Center discussed the efficacy of inebilizumab (Uplizna; Viela Bio) and biomarker data observed in the N-Momentum trial in NMOSD.

The Road to Accessible Biomarkers for Alzheimer Disease

June 24, 2020

Biomarkers in the cerebrospinal fluid and blood could hold the key to early diagnosis of Alzheimer disease.

Migraine Care During a Pandemic: Takeaways for the Future

June 24, 2020

In part 2 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, describes the lessons he and his residents have learned during the COVID-19 pandemic and how they'll impact the future of care.

TS Alliance Partners With Seizure Tracker to Promote Data Sharing

June 23, 2020

The partnership will combine 2 databases with robust historical data in hopes of empowering both research and physician communities and ultimately improving clinical care for patients with tuberous sclerosis complex.

Digital Therapeutic for Post-Stroke Walking Deficits Gets Breakthrough Designation

June 23, 2020

MedRhythms’ digital therapeutic platform serves as a digitized version of rhythmic auditory stimulation that is sensor-automated and music-based.

Chia-Chun Chiang, MD: Comparing Ubrogepant Study Results

June 23, 2020

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed whether her and colleagues recent study results on ubrogepant aligned with previous study findings.

Keeping Treatment Response "On" in Parkinson Disease

June 23, 2020

New drug classes and formulations may help hold off breakthrough activity as the research community works to optimize levodopa delivery and absorption.

Combination of Healthy Lifestyle Factors Reduces Alzheimer Risk

June 23, 2020

Compared to participants with ≤1 healthy lifestyle factor, the risk of developing Alzheimer disease was 37% lower in those with 2 or 3, and 60% lower in those with 4 or 5 healthy lifestyle factors.

Improving Stroke Systems of Care for Better Outcomes

June 22, 2020

The “time is brain” mantra continues to drive innovation in a specialty that will not settle for mediocrity.

Bruce Cree, MD, PhD, MAS: Inebilizumab for NMOSD Treatment

June 22, 2020

The clinical research director at the UCSF Multiple Sclerosis Center shared his perspective on the recent FDA approval of inebilizumab (Uplizna; Viela Bio) for NMOSD.

SRP-9001 Safe, Tolerable in Duchenne Muscular Dystrophy

June 22, 2020

Preliminary results showed that SRP-9001 is associated with clinically meaningful improvement that is greater than that observed with standard-of-care treatment, including corticosteroids.

Fred Cohen, MD: Combining CGRPs and OnabotulinumtoxinA for Migraine Prevention

June 22, 2020

The internal medicine resident physician at Montefiore Health System offers insight into the combined use of CGRP medications and Botox to optimize migraine prevention in patients who have inadequate response with Botox alone.

Investigational Pompe Disease Agent Avalglucosidase Alfa Shows Positive Results in Phase 3

June 22, 2020

The data, from the phase 3 COMET trial, will be the basis for global regulatory submissions in the second half of 2020, according to manufacturer Sanofi.

Cleveland Clinic Announces Women's Alzheimer Prevention Center

June 21, 2020

The Women's Alzheimer's Prevention Center becomes the first medical clinic in the US to offer a women-specific center for Alzheimer disease prevention, research, and caregiving support.

Neurology and COVID-19: Adapting Specialty Care During the Pandemic

June 20, 2020

In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.

Pimavanserin Gets NDA Nod, Ubrogepant Improves Chronic Migraine, Risdiplam Increases Motor Function

June 20, 2020

Neurology News Network for the week ending June 20, 2020.

Gilbert L'Italien, PhD: The Economic Impact of MIDAS Disability Grades in Migraine

June 20, 2020

The senior VP of Global Health Economics and Outcomes Research and Epidemiology at Biohaven Pharmaceuticals discussed the findings from a poster presentation on the economic impact of migraine disability at AHS 2020.

NeurologyLive Friday 5 — June 19, 2020

June 19, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.

Bruce Cree, MD, PhD, MAS: Inebilizumab's Impact on the NMOSD Landscape

June 19, 2020

The clinical research director at the UCSF Multiple Sclerosis Center discussed the anticipated impact of the recent FDA approval of inebilizumab (Uplizna; Viela Bio) for NMOSD.

High Frequency Episodic Migraine Has Similar Burden to Low Frequency Chronic Migraine

June 19, 2020

Treatment needs of those with high frequency episodic migraine may be similar to those with low frequency chronic migraine.

Ubrogepant Effective for Migraine Patients With Insufficient Triptan Response

June 19, 2020

The recently approved Allergan agent reported lower rates of functional disability and better overall satisfaction with treatment, as well as similar success for those who did not experience efficacy with triptans.

Daniel Ontaneda, MD, PhD: How Multiple Sclerosis Can Be Misdiagnosed

June 19, 2020

The neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis and co-principal investigator of the CAVS-MS study discusses the reasons for the high rates of misdiagnosed MS.

CMSC Announces 2nd Annual "More About MS" Forum

June 18, 2020

The online conference theme for this year is "Coming of Age with Multiple Sclerosis," and will feature the top neurologists and specialists within the multiple sclerosis community.

Matthew Robbins, MD: Experience Adjusting to COVID-19 in Migraine Care

June 18, 2020

The director of the Neurology Residency Program at Weill Cornell Medicine details his first-hand experience working in the epicenter of the COVID-19 pandemic and how his department adapted.

The Long-Term Impact of Addressing Gender Norms for Men With MS

June 18, 2020

In Part 2 of this interview, Bryan Davis, PsyD, MS, clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS, details the impact that conversations about masculinity norms in MS can have on future trials and care.

Migraine History Pre-Concussion Linked to Worse Symptoms Post-Injury

June 18, 2020

Patients with pre-concussion migraines that occurred at a rate of >1 per month had a greater number of concussion symptoms and burden over 12 weeks.

Atogepant Proves Safe Without ALT Elevation in Healthy Participants

June 18, 2020

Data presented at AHS 2020 suggest that 170-mg oral atogepant (Allergan) was both safe and well-tolerated, setting the stage the continued development in migraine prevention.

Nuplazid Heads to the FDA for New Indication for Dementia-Related Psychosis

June 17, 2020

The drug, previously approved for Parkinson disease psychosis, received breakthrough therapy designation for this new indication.

Celecoxib Oral Solution Offers Effective Alternative to Triptans in Acute Migraine

June 17, 2020

Data from a pair of phase 3 studies suggest that the recently approved celecoxib oral solution (Elyxyb; Dr. Reddy’s Laboratories) offers safe and effective acute treatment of episodic migraine.

Jessica Ailani, MD, FAHS: The Staying Power of Telemedicine in Headache

June 17, 2020

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed how this year has proved that telemedicine is likely here to stay.

OnabotulinumtoxinA Proves Safe as Migraine Treatment for Pregnant Women

June 17, 2020

Infants born to pregnant women with chronic migraine who received treatment with onabotulinumtoxinA did not show any physical, intellectual, or social disabilities.

New MRI Technique May Improve Tremor-Targeting Treatment in Parkinson Disease

June 17, 2020

The newly developed MRI techniques aimed at treating those with Parkinson disease could lead to better outcomes and fewer side effects.

Migraine With Aura Linked to High Risk of Dementia in Later Life

June 17, 2020

The results help to better understand the unique risk profiles of people with different subtypes of migraine.

Bryan Davis, PsyD, MS: Future Discussion on Masculinity Norms in MS

June 16, 2020

The clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research at Cleveland Clinic details the interventions for men with MS and how the study can change the discussion on masculinity norms.

Youth With Migraine Improve Post-Preventive Treatment Regardless of Therapy Continuation

June 16, 2020

Results from the CHAMP trial of adolescents and children with migraine add to the already active and ongoing discussion surrounding the use of preventives in this population.

Erenumab Shows Sustainable Efficacy in Refractory Episodic Migraine

June 16, 2020

Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.

Combination OnabotulinumtoxinA and CGRP Treatment Safe and Successful in Migraine

June 16, 2020

Further studies are needed to confirm the additional reductions in monthly headache days observed in patients with migraine who were treated with onabotulinumtoxinA and an add-on CGRP agent.

NIH Awards Cleveland Clinic Grant For MS Research

June 16, 2020

The $7.2 million grant will evaluate central vein sign as a biomarker for multiple sclerosis diagnosis.

Ubrogepant Shows Efficacy for Patients With Chronic and Episodic Migraine

June 15, 2020

Consistent pain relief from all attacks was reported by 27% of patients treated with ubrogepant and 73% experienced relief from at least 1 attack.

Risdiplam Significantly Improves SMA Motor Function After 24 Months

June 15, 2020

Preliminary 12-month data from the JEWELFISH study in previously treated patients showed rapid and sustained increases in survival motor neuron protein levels.

Intranasal DHE Meets Primary Objectives in Treatment of Acute Migraine

June 15, 2020

Impel NeuroPharma, the agent’s developer, is on target for submission of a new drug application for the treatment in the second half of 2020.

Cefaly Migraine Device Expands Access in Partnership With Azova

June 15, 2020

The device will now be available with prescription through Azova’s Collaborative Clinical Care Platform for those with migraine.

Intracranial Hemorrhage Incidence Increases With Age

June 14, 2020

Emphasis on prevention of intracranial hemorrhage at an early stage is recommended to mitigate further risks later in a patient’s life, especially in older individuals.

Jessica Ailani, MD: New Approvals and Nonpharmacologic Options for Headache

June 13, 2020

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital spoke to the specific datasets she is anticipating at the AHS 2020 meeting.

Why Learning About Masculine Norms Can Improve MS Care

June 13, 2020

In Part 1 of this interview, the clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research provides in-depth insight on his study evaluating masculinity norms in patients with multiple sclerosis.

Lemborexant and Ozanimod Available, Migraine and Stroke During Pregnancy, NDA Accepted for Amantadine

June 13, 2020

Neurology News Network for the week ending June 13, 2020.

NeurologyLive Friday 5 — June 12, 2020

June 12, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 12, 2020.

AHS 2020: What to Expect From the Annual Scientific Meeting

June 12, 2020

Ahead of sessions kicking off on June 13, Jessica Ailani, MD, FAHS, offers a look into what data, plenary talks, and developments are set to be presented at the upcoming AHS 2020 annual meeting.

Inebilizumab Approved for Treatment of Neuromyelitis Optica Spectrum Disorder

June 12, 2020

The treatment, marketed as Uplizna, is only the second approved therapy for NMOSD.

Stroke Treatment Gap Between Men and Women Has Narrowed

June 12, 2020

Despite the likelihood of women receiving IV thrombolysis still being 13% lower than men, the gap narrowed by 17% from 2008 to 2018 compared to what was observed from 2000 to 2008.

Bryan Davis, PsyD, MS: Behavioral Health and CMNI in Treating MS

June 11, 2020

The clinical health psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic details the use of behavioral health and potential use of Conformity to Masculine Norms Inventory (CMNI) tool in multiple sclerosis care.

Vascular Risk and White Matter Burden Differ by Stroke Classification Subtype

June 11, 2020

Effectively addressing vascular risk factors could provide an important avenue for modifying white matter hyperintensity disease burden.

Jessica Ailani, MD: The Ongoing Expansion in Headache Medicine

June 11, 2020

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to the rapid expansion of headache medicine and what new research will be discussed at AHS 2020.

Nusinersen-Treated Patients With SMA Experience Unprecedented Survival

June 11, 2020

The new data from the phase 2 NURTURE study are set to be presented at the virtual Cure SMA Research and Clinical Care Meeting.

Stroke Risk May Be More Than Doubled for Black Smokers

June 10, 2020

Results of the Jackson Heart Study suggest that cigarette smoking is linked with a dose-dependent higher risk of all stroke in black individuals compared to those who did not smoke.

Relapsing Multiple Sclerosis Disability Not Linked to Overt Relapses

June 10, 2020

An overwhelming number of patients with relapsing multiple sclerosis may accumulate disability due to underlying progressive disease course independent of relapse activity.

Cure SMA Announces New Funding for Network of SMA Research and Treatment Centers

June 10, 2020

The funding for the Pediatric Neuromuscular Clinical Research Network will provide assistance to some of the world's highly skilled clinical trial investigators who have led studies that have resulted in numerous FDA approvals of breakthrough treatments.

Neurologic Complications Common in Patients With COVID-19

June 10, 2020

The study confirmed previous study findings that indicated potential severe conditions such as stroke or inflammatory diseases can appear in later stages of COVID-19, including during recovery.

Jessica Ailani, MD: Plenary Talks at the AHS 2020 Annual Meeting

June 09, 2020

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed what topics the plenary talks will cover at AHS 2020.

Investigational Limb-Girdle Muscular Dystrophy Gene Therapy Positive in Phase 1/2

June 09, 2020

Data show the therapy’s positive safety and expression results from a small number of clinical trial participants with limb-girdle muscular dystrophy type 2E out to 1 year.

Kathleen Hawker, MD: Clinical Findings for Satralizumab in Treating NMOSD

June 09, 2020

The group medical director of neuroscience at Genentech spoke to the findings recently presented at the 6th Annual Meeting of the European Academy of Neurology.

Natalizumab Sets Itself Apart From Other MS Treatments

June 09, 2020

Carrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.

New Agents Now Available for Insomnia and Multiple Sclerosis

June 09, 2020

After respective approvals in December 2019 and March 2020, lemborexant (Dayvigo; Eisai) and ozanimod (Zeposia; Bristol Myers Squibb) have become available for patients with insomnia and multiple sclerosis.

Jessica Ailani, MD: What to Expect From the American Headache Society Meeting

June 08, 2020

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to what to expect from this year’s annual scientific meeting.

Endovascular Treatment Has No Added Benefit on Cerebral Venous Thrombosis Outcomes

June 08, 2020

Coutinho et al. noted that future studies that feature a larger population will help to better determine recovery rates after endovascular treatment.

Elevated Risk of Stroke Associated With Migraine in Pregnant Women

June 08, 2020

Approximately one-fourth of the excess cases of maternal stroke associated with migraine were attributable to hypertensive disorders.

What Impact Will the Tauvid PET Tracer Approval Have in Alzheimer Disease?

June 07, 2020

The founding executive director and chief science officer of the Alzheimer’s Drug Discovery Foundation discussed the recent approval of the imaging agent flortaucipir F18.

Bryan Davis, PsyD, MS: Exploring Masculinity Norms in MS

June 06, 2020

The clinical healthy psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the reasoning behind his study evaluating conformity of masculine norms in patients with multiple sclerosis.

Withdrawal Plus Preventive Treatment Superior to Treat Medication Overuse Headache

June 06, 2020

The first study to attempt to directly compare 3 debated treatment strategies to treat medication overuse headache showed the most significant change in monthly headache days by using withdrawal plus preventive treatment.

FDA Delays Ofatumumab Decision, Yoga Improves Migraine, Ticagrelor Gains FDA Approval

June 06, 2020

Neurology News Network for the week ending June 6, 2020.

Fernando Dangond, MD, MBA: Phase 2 Data on Evobrutinib in MS

June 05, 2020

Head of Global Clinical Development in Neurology at EMD Serono discussed the findings of a phase 2 assessment of the company’s investigational BTK inhibitor evobrutinib in multiple sclerosis.

NeurologyLive Friday 5 — June 5, 2020

June 05, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 5, 2020.

Supplemental Application for Amantadine ER Capsules Accepted for Review

June 05, 2020

The Adamas Pharmaceuticals agent has a PDUFA action date of February 1, 2021, as a treatment for off episodes in patients with Parkinson disease who are receiving levodopa-based therapy.

Episode 11: Exploring the Link Between Stroke and COVID-19

June 05, 2020

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Shadi Yaghi, MD.

Viltolarsen Induces De Novo Dystrophin Production in Duchenne Muscular Dystrophy

June 05, 2020

The Nippon Shinkyaku therapy also showed no treatment-emergent adverse events that required reduction, interruption, or discontinuation of the treatment.

Early Dementia Is Associated With Significant Financial Burden for Patients and Caregivers

June 05, 2020

The GERA-US study assessed societal costs associated with MCI and mild dementia, and caring for someone with Alzheimer disease, and was the first such study to show how the early stages of cognitive decline economically impact both patients and their caregivers.

Baseline Dyskinesia Linked to Adverse Event Dyskinesia While on Istradefylline

June 04, 2020

Post-hoc data presented at the EAN Congress suggest patients with dyskinesia prior to starting treatment on the Kyowa Kirin agent were more likely to experience dyskinesia as an adverse event during treatment.

Shadi Yaghi, MD: Future Research on Stroke and COVID-19

June 04, 2020

The assistant professor and director of Clinical Vascular Neurology Research at NYU Langone shares his reaction to data that has been published and what needs to be researched going forward.

Galcanezumab Improves Work Productivity, Reduces Interictal Burden

June 04, 2020

Non-work-related activity impairment was statistically significantly reduced in the galcanezumab group compared to placebo.

James Wheless, MD: Consequences of Virtual Societal Meetings

June 04, 2020

The chief of pediatric neurology at the University of Tennessee Health Science Center, and director of the Comprehensive Epilepsy Program at Le Bonheur Children's Hospital spoke to the difficulty in connecting with colleagues with virtual meetings.

REM Sleep Behavior Disorder Shows No Link to Impulse Control Behaviors in Parkinson

June 03, 2020

Incident impulse control disorder behaviors through the 5-year follow-up period were correlated with dopamine agonist use and depression, but not with age.

Increased Risk of Post-Dural Puncture Headache Associated With Lower Glucose Levels

June 03, 2020

Raising glucose levels may prove to be a simple and novel technique for the prevention and treatment of post-dural puncture headache.

FDA Delays Ofatumumab Decision in Multiple Sclerosis

June 03, 2020

The anti-CD20 monoclonal antibody had an original PDUFA date of June 2020.

The Advantages of Independent Contact-Current Controlled DBS Devices

June 03, 2020

The professor and head of the department of neurology at the University of Minnesota spoke to the recent findings of a study of Boston Scientific's multiple independent contact current-controlled device for deep brain stimulation.

Cenobamate Significantly Improves Seizure Control in Adults With Uncontrolled Focal Seizures

June 02, 2020

Cenobamate may offer a potential treatment option for patients who continue to have seizures despite the use of available treatments.

Add-On Yoga May Benefit Patients With Migraine

June 02, 2020

The study authors noted that the findings suggest that integrating a cost-effective and safe intervention such as yoga into the management of migraine would be beneficial.

James Wheless, MD: Treatment Development in Epilepsy

June 02, 2020

The chief of pediatric neurology at the University of Tennessee Health Science Center, and director of the Comprehensive Epilepsy Program at Le Bonheur Children's Hospital discussed the current state of research in epilepsy care.

Arimoclomol Granted Fast Track Designation for Amyotrophic Lateral Sclerosis

June 02, 2020

Topline results from the phase 3 trial of arimoclomol are expected to be announced in the first half of 2021.

Jerrold L. Vitek, MD, PhD: Multiple Independent Contact Current-Controlled DBS Technology

June 01, 2020

The professor and head of the department of neurology at the University of Minnesota discussed what multiple independent contact current-controlled devices offer physicians conducting deep brain stimulation.

FDA Approves Ticagrelor for Stroke Risk Reduction in Patients With Coronary Artery Disease

June 01, 2020

This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy in patients who have a high cardiovascular event risk, but without a history of heart attack or stroke.

Efgartigimod Meets Primary End Point in Myasthenia Gravis

June 01, 2020

The agent’s developer, Argenx, stated that it plans on submitting a biologics license application (BLA) to the FDA by the end of 2020.

Novel BTK Inhibitor Evobrutinib Displays Long-Term Success in MS

June 01, 2020

The vice president of Global Program Leadership in Neurology and Immunology at EMD Serono discussed the recent long-term phase 2 data on evobrutinib presented at CMSC 2020.

Vercise DBS System Shows Safety and Efficacy in Treating Parkinson Motor Symptoms

May 31, 2020

From post-implantation screening to 3 months, those in the active treatment arm reported a mean improvement of 3.03 more hours of on time than the control group with Boston Scientific’s deep brain stimulation device.

Acute Stroke Predicts Negative Outcome in COVID-19 Patients With Neuroimaging Findings

May 30, 2020

Patients with acute large ischemic and hemorrhage stroke had much higher mortality risk adjusted for age.

Ofatumumab Increases NEDA Status, Apomorphine FDA Approved, Siponimod Reduces Risk of CDP

May 30, 2020

Neurology News Network for the week ending May 30, 2020.

CMSC 2020 Day 4: Sarah Morrow, MD, MS, on a Clinician's Guide to Cognition in MS

May 30, 2020

Sarah Morrow, MD, MS, presents her lecture titled, "A Clinician’s Guide to Cognition in MS" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 4: Jennifer Graves, MD, PhD, on the Role of Biological Aging in MS Progression

May 30, 2020

Jennifer Graves, MD, PhD, presents her lecture titled, "The Role of Biological Aging in MS Progression" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 4: Riley Bove, MD, on Caring for Women Across the Reproductive Lifespan

May 30, 2020

Riley Bove, MD, presents her lecture titled, "Caring for Women Across the Reproductive Lifespan" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 4: Horea Rus, MD, PhD, on the Role of Complement in MS

May 30, 2020

Horea Rus, MD, PhD, delivers his lecture titled, "The Role of Complement in MS" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 4: Sergio Baranzini, PhD With a Genetics Update in MS

May 30, 2020

Sergio Baranzini, PhD, presents his lecture titled, "Genetics Update" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 3: Mark Freedman, MSc, MD, on Stem Cell Research

May 30, 2020

Mark Freedman, MSc, MD, presents the John F. Kurtzke Lecture, titled "Stem Cell Research Update" as part of the 2020 CMSC Virtual Annual Meeting.

NeurologyLive Friday 5 — May 29, 2020

May 29, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.

CMSC to Host Mini Poster Session & Product Theaters

May 29, 2020

Following the 2020 Consortium of Multiple Sclerosis Centers Virtual Annual Meeting, the organization has scheduled a mini poster session and product theaters for June 1-14.

Aerobic Exercise Shows Positive Effect in Multiple Sclerosis

May 29, 2020

Improvements in function may be mediated by an effect of aerobic fitness on deep gray matter brain structures.

Matthew B. Harms, MD: Amyotrophic Lateral Sclerosis Updates

May 29, 2020

The consultant for the Muscular Dystrophy Association’s Chief Medical Advisory Team and associate professor of neurology at Columbia University offered his perspective on some of the latest news in ALS.

Cladribine Deemed Well-Tolerated in MS Treatment, Could Influence Adherence Rates

May 29, 2020

An analysis of data from the phase 3 development of cladribine (Mavenclad; EMD Serono) showed that the incidence of treatment-emergent adverse events was low and most were mild in intensity.

CMSC 2020 Day 3: Laura Safar, MD on Use of Psychotropics in MS

May 29, 2020

Laura Safar, MD, presents her lecture titled, "Use of Psychotropics in MS: Antidepressants, Anti-anxiety Agents, Mood Stabilizers, Hypnotics, Antipsychotics, and Cognitive Enhancers" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 3: Allen Bowling, MD, PhD, on Cannabis and MS

May 29, 2020

Allen Bowling, MD, PhD, presents his lecture titled, "Cannabis and MS: Efficacy, Safety, Drug Interactions, and Research Update" as part of the 2020 CMSC Virtual Annual Meeting.

First Tau Imaging Agent for Alzheimer Disease FDA-Approved

May 29, 2020

Marketed as Tauvid by Avid Radiopharmaceuticals, the flortaucipir F18 IV injection is indicated to be used with PET imaging to assess the distribution and density of aggregated tau neurofibrillary tangles.

CMSC 2020 Day 3: Benjamin Greenberg, MD, on Emerging Therapies Across the Disease Spectrum

May 29, 2020

Benjamin Greenberg, MD, presents his lecture titled, "Emerging Therapies Across the Disease Spectrum" as part of the 2020 CMSC Virtual Annual Meeting.

Peter Nakaji, MD: The State of Science for Epilepsy Surgery

May 29, 2020

The chair of the Department of Neurosurgery at Banner-University Medical Center discusses the current state of the science being done in the realm of epilepsy surgery.

Levels of GFAP Higher in NMOSD, Suggesting It May Serve as a Biomarker

May 28, 2020

A subset group of inebilizumab-treated patients who did not have adjudicated attacks displayed more than a 2-fold increase in serum CSF glial fibrillary acidic protein from baseline, implying GFAP may serve as a biomarker.

Pediatric MS Disease Activity May Increase Upon Menarche

May 28, 2020

Findings from a study of more than 500 girls with multiple sclerosis suggest that first menstruation and the onset of puberty may be a time of increased disease activity in pediatric MS.

CMSC 2020 Day 2: Patricia Bobryk, MHS, PT, MSCS, ATP, on Rehab in MS: That Was Then, This Is Now

May 28, 2020

Patricia Bobryk, MHS, PT, MSCS, ATP, presents her lecture titled, "Rehabilitation in MS: That Was Then, This Is Now" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 2: Brenda Banwell, MD, on Current Perspectives of Pediatric MS Care and Research

May 28, 2020

Brenda Banwell, MD, presents her lecture titled, "Current Perspectives of Pediatric MS Care and Research" as part of the 2020 CMSC Virtual Annual Meeting.

Satralizumab Shows Safe Profile in Patients With NMOSD

May 28, 2020

Data from the overall satralizumab treatment period, which expanded on the double-blind periods by adding new data from the ongoing open-label extension periods, were consistent with the double-blind period results.

Shadi Yaghi, MD: Incidence of Stroke in Patients With COVID-19

May 28, 2020

The assistant professor and director of Clinical Vascular Neurology Research at NYU Langone gives perspective on his recent study of patients with stroke and COVID-19 and the difficulties in understanding their relationship.

CMSC 2020 Day 2: Mona Bostick, RDN, LDN, on the Importance of Nutritional Health in Patients With MS

May 28, 2020

Mona Bostick, RDN, LDN, presents her lecture titled, "The Importance of Assessing Nutritional Health in Patients With MS" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 2: Anthony Feinstein, MPhil, PhD, on Diagnosing and Treating Depression in MS

May 28, 2020

Anthony Feinstein, MPhil, PhD, FRCP, presents his lecture titled, "Depression and MS: Diagnosing and Treating" as part of the 2020 CMSC Virtual Annual Meeting.

MSProDiscuss Tool Is Usable and Useful in MS Clinical Practice

May 27, 2020

A real-world survey of more than 300 health care practitioners suggests that the MSProDiscuss tool offers a useful tool for the physician-patient discussion on multiple sclerosis disease progression.

Howard Fillit, MD: ADDF Diagnostics Accelerator Initiative

May 27, 2020

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed goals and current work being conducted by its Diagnostics Accelerator initiative.

Natalizumab Provides Superior 'Feel Good' Experience in MS Over Other Treatments

May 27, 2020

Increases in physical, emotional, and cognitive functioning were more common in patients receiving natalizumab than in patients receiving other disease modifying therapies.

Siponimod Reduces Risk of Disability Progression Regardless of Prior Relapses in MS

May 27, 2020

The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.

Richard Finkel, MD: Goals of St. Jude Center for Experimental Neurotherapeutics

May 27, 2020

The newly appointed director for the Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital details his personal responsibilities and the long-term goals for the new center.

CMSC 2020 Day 1: Patricia Melville, Marijean Buhse, PhD, on Comorbidities and Critical Thinking About DMTs and Vaccines

May 27, 2020

Patricia Melville, NP-C, MSCN, and Marijean Buhse, PhD, NP-C, MSCN, present their lecture titled, "Comorbidities and MS: Critical Thinking About DMTs and Vaccines" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 1: Peter Calabresi, MD, on CNS Immune Responses in Progressive MS

May 27, 2020

Peter Calabresi, MD, delivers the Whitaker Lecture as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 1: Amy Sullivan, PsyD, ABPP, on Science, Art, and Practice of Behavioral Medicine in MS

May 27, 2020

Amy Sullivan, PsyD, ABPP, presents her lecture titled, "Science, Art, and Practice of Behavioral Medicine" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 1: Brian Weinshenker, MD, on Emerging Treatment Options for NMOSD

May 27, 2020

Brian Weinshenker, MD presents his lecture titled, "Neuromyelitis Optica Spectrum Disorders: Emerging Treatment Options" as part of the 2020 CMSC Virtual Annual Meeting.

CMSC 2020 Day 1: Patricia Coyle, MD on Diagnosis, Clinical Course, and Long-Term Management of Progressive MS

May 27, 2020

Patricia Coyle, MD, delivers her lecture titled, "Progressive MS: Diagnosis, Clinical Course and Long-Term Management" as part of the 2020 CMSC Virtual Annual Meeting.

Evobrutinib Shows Long-Term Efficacy and Safety in Phase 2 Study

May 26, 2020

Evobrutinib, a highly selective BTK inhibitor for the treatment of relapsing multiple sclerosis, showed long-term safety and success in reducing annualized relapse rates.

Ocrelizumab Has Similar Effects in MS With Shorter Infusion Time

May 26, 2020

The Genentech agent, which is approved for patients with relapsing-remitting multiple sclerosis, showed no new safety signals in a comparison between conventional and shorter infusion times.

Ofatumumab Increases NEDA-3 Likelihood in MS Compared With Teriflunomide

May 26, 2020

Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.

Elevated Plasma NfL Levels Linked to Worse Disability in Multiple Sclerosis

May 25, 2020

Plasma neurofilament light chain (pNfL) may serve as a prognostic tool to assess the risk of developing permanent disability in multiple sclerosis.

Steven Shook, MD: Managing Patients Via Telemedicine

May 25, 2020

The staff neurologist, Vice-Chair of Operations, and Quality Improvement Officer at Cleveland Clinic Neurological Institute detailed his experience managing patients with various conditions through a telemedicine platform.

Jennifer Frontera, MD: Reaction to COVID-19 Data

May 24, 2020

The professor of neurology at NYU Langone shares her thoughts on the clinical data that has been released so far on patients with COVID-19.

The Importance of Interdisciplinary Care in MS

May 23, 2020

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.

COVID-19 Stroke Recommendations, Nusinersen New SMA Results, Upcoming 2020 CMSC Virtual Annual Meeting

May 23, 2020

Neurology News Network for the week ending May 23, 2020.

NeurologyLive Friday 5 — May 22, 2020

May 22, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

NIH Data Suggest Brain Glucose Metabolism Is Linked to Alzheimer Pathogenesis

May 22, 2020

The data included more than 2000 brains and approximately 400 cerebrospinal fluid samples, and showed that a protein network module linked to glucose metabolism was also elevated in cerebrospinal fluid in early stages of the disease.

Mark Freedman, MD: An Update on Stem Cell Research in MS

May 22, 2020

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.

Second Dose of Ubrogepant Is Safe and Effective in Acute Migraine

May 22, 2020

The study author, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of a pooled analysis of the ACHIEVE I and II studies of ubrogepant.

Apomorphine Sublingual Film Approved for Motor Fluctuations in Parkinson Disease

May 22, 2020

The drug is the first on-demand off episode treatment to be administered sublingually.

Glatopa Has Similar Outcomes and Cost Compared With Copaxone

May 21, 2020

The first study to examine the impact on real-world outcomes and costs of switching patients with MS from Copaxone to Glatopa revealed few significant differences.

Brenda Banwell, MD: Current Perspectives on Pediatric MS Care and Research

May 21, 2020

The chief of the Division of Neurology at Children’s Hospital of Philadelphia spoke to the need for clinical trial evidence and research for the pediatric MS population.

Tardive Dyskinesia Worsens Quality of Life in Patients With Psychiatric Disorders

May 21, 2020

The data support the need to raise awareness of involuntary movements from possible tardive dyskinesia and the importance of properly screening and diagnosing patients.

Andrew Blumenfeld, MD: Long-Term OnabotulimuntoxinA Use in the COMPEL Study

May 20, 2020

The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.

Plasma P-Tau181 Biomarker May Be Accessible, Scalable Test for Alzheimer Disease

May 20, 2020

Findings from an analysis of a large population of individuals suggest that the blood immunoassay can predict tau and amyloid-ß pathologies, as well as differentiate and identify Alzheimer disease across the clinical spectrum.

Amy Sullivan, PsyD, ABPP: Interdisciplinary Care in MS

May 20, 2020

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.

CMSC To Launch Virtual Educational & Exhibit Programs

May 20, 2020

In addition to the 2020 CMSC Virtual Meeting, attendees will be eligible to earn up to an additional 18 contact hours of continuing education.

2020 EMD Serono Nightingale Award Announced

May 20, 2020

Recipients of the award will be provided additional funding that will go to support porgrams for MS patients and their care partners.

Ofatumumab Shines in Pooled Comparative Analysis in Relapsing Multiple Sclerosis

May 20, 2020

The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.

Howard Fillit, MD: Aducanumab Findings Lead the Way in Dementia

May 20, 2020

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the landmark findings from Biogen on its agent aducanumab and the impact the trial might have on the future.

Poorer Cognitive Performance Post-Stroke Observed in Patients With Diabetes

May 20, 2020

Compared to those with normal fasting glucose levels, those with Type 2 diabetes had poorer cognitive performance at 3 and 6 months after suffering a stroke, based on data from the STROKOG consortium.

NeurologyLive Adds Cure SMA to Its Strategic Alliance Partnership Program

May 20, 2020

Cure SMA joins the list of influential and impactful organizations within the Strategic Alliance Program.

Analysis Suggests No Link Between OSA and Postoperative Delirium

May 20, 2020

Contrary to prior literature, a new single-center analysis suggests that obstructive sleep apnea is not associated with delirium in those who were postoperatively admitted to the ICU, though PAP may reduce delirium in this patient population.

Residential Segregation Leads to Worse Cognition in Black Individuals

May 19, 2020

The association between black individuals and processing speeds may explain the black-white disparities in dementia risk at older age.

Steven Shook, MD: Transitioning to Telemedicine

May 19, 2020

The staff neurologist, Vice-Chair of Operations, and Quality Improvement Officer at Cleveland Clinic Neurological Institute discussed the institute’s transition to telemedicine and how it has been utilized.

Nusinersen Shows Efficacy in Infantile- and Late-Onset Spinal Muscular Atrophy

May 19, 2020

The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.

Risk of Cardiovascular Disease Increased in Those With Multiple Sclerosis

May 18, 2020

Women with multiple sclerosis had a greater risk of macrovascular disease than men, which was consistent with previous studies.

Richard Finkel, MD: Specific Neurologic Focus at New St. Jude Center

May 18, 2020

The newly appointed director for the Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital gives an overview on what neurologic disorders the new center will focus on.

Recommendations for Prehospital Stroke Care During COVID-19 Published

May 18, 2020

During the COVID-19 pandemic, it is more important than ever to ensure that a patient with stroke is transferred to the right hospital the first time around.

Satralizumab Shows Potential in NMOSD With FDA Approval Pending

May 18, 2020

With an FDA decision on a BLA for the Genentech agent expected later this year, the Group Medical Director of Neuroscience at Genentech shared insight on recent findings of satralizumab in NMOSD.

ADDF Diagnostic Accelerator Initiative Invests In Digital Memory Impairment Projects

May 17, 2020

The Alzheimer’s Drug Discovery Foundation made 5 new investments through its Diagnostics Accelerator initiative, through which it has $50 million in commitments from leading scientific philanthropists such as Leonard A. Lauder, Bill Gates, Jeff Bezos, and MacKenzie Bezos.

Combination of AI, MRI Can Predict Alzheimer Disease Risk

May 16, 2020

Artificial intelligence unlocks new potential to expand neuroimaging tools and techniques available for disease detection and prevention.

NeurologyLive Friday 5 — May 15, 2020

May 15, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 15, 2020.

Adjusting Epilepsy Care During the COVID-19 Pandemic

May 15, 2020

The director of pediatric epilepsy and professor of neurology at Mayo Clinic detailed how care for patients with epilepsy has changed during the COVID-19 pandemic.

Episode 10: Neurology and COVID-19: Perspectives From the Front Line

May 15, 2020

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Frontera, MD.

Those With Epilepsy Report High Psychological Distress During Public Health Emergencies

May 15, 2020

A cross-sectional, case-control study’s findings imply that patients with epilepsy may be experiencing high rates of psychological distress amid the COVID-19 pandemic.

Satralizumab Monotherapy Effective in Neuromyelitis Optica Spectrum Disorder

May 14, 2020

The data from the SAkuraStar study on satralizumab add to the total literature on the Genentech humanized monoclonal antibody, which is set for FDA decision later this year.

Richard Finkel, MD: St. Jude Takes Major Step in Neurology Sphere

May 14, 2020

Finkel discussed his new role at St. Jude Children’s Research Hospital, where he'll head up the new Center for Experimental Neurotherapeutics.

MRI Reveals Brain Abnormalities in COVID-19 Patients

May 14, 2020

Evidence continues to increase on the neurological impacts of COVID-19 infection, with patients admitted to the intensive care unit (ICU) showing brain abnormalities on MRI scans.

AID-P Provides Most Accurate Differentiator of Parkinson Disease

May 14, 2020

Automated Imaging Differentiation in Parkinsonism (AID-P) outperformed both the Magnetic Resonance Parkinsonism Index and neurofilament light chain protein in differentiating PD from atypical parkinsonism.

Interim Analysis Suggests Sovateltide Is Successful in Acute Ischemic Stroke

May 14, 2020

Pharmazz, the developer of the endothelin-B receptor agonist, noted that it plans to move forward with an investigational new drug submission to the FDA for sovateltide.

Jennifer Robblee, MD: The Influence of Telemedicine and Social Media on Medicine

May 14, 2020

The neurologist at the Barrow Neurological Institute spoke to the impact that social media and telemedicine have had on the medical community’s ability to stay connected and continue to provide care and support.

Recommendations Published for Preserving Stroke Care During the COVID-19 Pandemic

May 13, 2020

Amid swirling reports of associations between stroke and the novel coronavirus, as well as the impact the pandemic has had on stroke care, new recommendations to maintain care expectations have been suggested by a diverse group of stroke experts.

FT218 Meets Primary End Point in Phase 3, Lowers Weekly Cataplexy Attacks

May 13, 2020

Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Steve Chung, MD: Cannabidiol in Tuberous Sclerosis Complex

May 13, 2020

The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.

The State of Stroke Care: Adjusting to COVID-19 and Recent Research

May 13, 2020

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute discussed the possible link between COVID-19 and stroke and offered an update on recent research in the stroke care landscape.

Portable Neuromodulation Stimulator Device Gets Breakthrough Designation for MS

May 13, 2020

Helius’s short-term treatment PoNS device has been approved for use in Canada, and is intended to be used alongside physical therapy for gait deficit due to mild and moderate symptoms of MS.

Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine

May 12, 2020

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.

BAN2401 Linked to Persistent Negative Amyloid PET in Alzheimer Disease

May 12, 2020

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.

Earlier Treatment Linked to Better Outcomes in Sleep-Disordered Breathing

May 12, 2020

System interventions could be used to modify patient behavior, leading to improved adherence and better clinical outcomes for those with sleep-disordered breathing, according to new data.

Jennifer Frontera, MD: Utilizing Hospitals Amid COVID-19

May 12, 2020

The professor of neurology at NYU Langone gives her input on those who are nervous to take hospital trips, as well as the protocol for patients with neurological disorders as COVID-19 slows down.

Eteplirsen Slows Pulmonary Decline in Duchenne Muscular Dystrophy

May 11, 2020

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.

Jennifer Robblee, MD: Mitigating Safety Concerns for Telemedicine Exams

May 11, 2020

The neurologist at the Barrow Neurological Institute discussed how to best address telemedicine appointments and exams for patients who may be at risk for a fall or some other safety concern.

Study Identifies Inconsistencies Among Genetic Testing for Epilepsy

May 11, 2020

Data suggest that discrepancies in genetic testing for epilepsy warrant second opinions for interpretations as well as clinical reports that become part of a patient’s medical record following a second opinion.

The Association Between Retinal Atrophy and BMI in Multiple Sclerosis

May 11, 2020

The trio of authors from Johns Hopkins discussed the findings of a study that imply that BMI is associated with accelerated rates of ganglion cell and inner plexiform layer atrophy in those with multiple sclerosis.

Cold Extremities Linked to More Frequent Migraine Attacks in Women

May 09, 2020

Women with migraine with cold extremities had higher attack frequencies, which data suggest stems partly from sleep disturbances.

MS Physical Activity Recommendations, FDA Approves Celecoxib, Rituximab Effect on Myasthenia Gravis

May 09, 2020

Neurology News Network for the week ending May 9, 2020.

PREEMPT Protocol Is Adjusted Frequently, Raising Questions for Clinicians

May 09, 2020

The clinical neurology fellow at Brigham and Women's Hospital and Harvard University detailed what recent survey data suggest, why the survey was conducted, and how to possibly improve the approach to the protocol.

NeurologyLive Friday 5 — May 8, 2020

May 08, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 8, 2020.

Clinicians Report Inconsistencies in Treating Migraine With PREEMPT Protocol

May 08, 2020

The wide variance in onabotunlinumtoxinA use for migraine prevention raises the question of whether evidence-based advisory statements might be more helpful than a proscriptive protocol.

Nina Riggins, MD, PhD: The Effect of Dihydroergotamine Infusion Rates

May 08, 2020

The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes.

BMI May Be Linked to Accelerated Retinal Atrophy in Multiple Sclerosis

May 08, 2020

An identified association between accelerated rates of ganglion cell and inner plexiform layer atrophy in the absence of overt metabolic comorbidities suggests that obesity may affect accelerated neurodegeneration in those with multiple sclerosis.

Steve Chung, MD: Perampanel's Effect on Insomnia in Patients With Epilepsy

May 08, 2020

The neurologist at Banner-University Medicine Neuroscience Institute discussed the findings of a study that suggest perampanel may improve insomnia by decreasing anxiety in patients with epilepsy.

Gaboxadol Reports Positive Topline Results in Phase 2 for Fragile X Syndrome

May 07, 2020

Data showed that Ovid Therapeutics’ gaboxadol, also known as OV101, was well-tolerated and had a significant effect on secondary behavioral end points in the 3 combined study groups.

Cenobamate Reduces Seizure Frequency Regardless of Concomitant AEDs

May 07, 2020

Treatment with SK Life Science’s cenobamate showed higher responder rates than placebo, regardless of baseline seizure frequency or disease duration.

Elaine Wirrell, MD: Adjusting Epilepsy Care For Telemedicine

May 07, 2020

The director of pediatric epilepsy and professor of neurology at Mayo Clinic details the rampant acceleration of telemedicine and how her practice is adjusting to the COVID-19 pandemic.

Bridging Therapy Effective for Stroke With M1 Occlusions

May 07, 2020

The first study to assess the effect of endovascular therapy added on to intravenous thrombolysis uncovered more evidence of its effect on specific occlusions rather than overall outcomes.

Howard Fillit, MD: Telemedicine and Tech in the Future Care of Alzheimer and Dementia

May 06, 2020

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation detailed what he foresees the future of Alzheimer and dementia care to look like with telemedicine as a more permanent aspect of care.

Flortaucipir PET Tracer Accurately Supports Alzheimer Disease Pathology

May 06, 2020

The positron emission tomography tau tracer was shown to identify high levels of Alzheimer disease neuropathologic change and neurofibrillary tangles with good sensitivity and specificity.

Jeremy Payne, MD, PhD: The Lack of Progress for Telestroke

May 06, 2020

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute spoke to the need for data like that from the TELECAST study and how the COVID-19 pandemic might push telestroke care forward.

Inotersen Slows Progression of hATTR Amyloidosis

May 06, 2020

Early treatment with Ionis Pharmaceuticals’s inotersen resulted in greater long-term disease stabilization than delayed initiation.

Celecoxib Oral Solution Approved for Acute Migraine

May 06, 2020

The COX-2 inhibitor was OK’d for the treatment of acute migraine in adults with or without aura more than 20 years after the drug's initial approval for pain indications.

Neurologic Features of COVID-19 Patients Reported, Including Those With Guillain-Barre

May 06, 2020

The case-based reports ultimately suggest that more data collection is required, but highlight the observations of more than 60 patients, including a 5-patient cohort with Guillain-Barré syndrome.

Reena Mehra, MD, MS: Advances in Sleep Apnea Treatment Devices

May 05, 2020

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine detailed the advancements that have been made with OSA treatment devices.

Vitamin D, Smoking Conversely Predict Cognitive Function in Multiple Sclerosis

May 05, 2020

Data led the authors to believe that vitamin D might have neuroprotective properties and that levels may be a prognostic marker of long-term cognition and neuroaxonal integrity.

Rituximab May Be More Effective in Early-Onset Myasthenia Gravis

May 05, 2020

This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis.

Bhooma Aravamuthan, MD, DPhil: Taking a Multi-Specialist Approach to Cerebral Palsy

May 04, 2020

The assistant professor of neurology at the University of Washington in St. Louis discussed the need for a systemic, multi-specialist approach to cerebral palsy and provided the main takeaways from her and her colleagues’ work.

CMSC, National MS Society Release Multiple Sclerosis Physical Activity Recommendations

May 04, 2020

The exercise and physical activity recommendations were tailored to individuals with differing disability levels on the Expanded Disability Status Scale.

Jeremy Payne, MD, PhD: The Need to Improve Telestroke Care

May 04, 2020

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute discussed how data from the TELECAST trial impact existing literature and the areas of improvement for the current use of telemedicine for stroke.

Fenfluramine-Reduced Seizure Frequency in Dravet Improves Executive Function

May 04, 2020

Treatment with fenfluramine was associated with greater seizure reduction, which in turn improved executive function over time in patients with Dravet syndrome.

AAN Releases Updated Advisory for PFO Closure in Stroke

May 03, 2020

In an update to the 2016 practice advisory, new data have shifted recommendations to include the consideration of PFO closure for select patients under the age of 60.

FDA Clears Point-of-Care MRI System

May 02, 2020

Evry will soon be commercially available in the US and will provide MRI imaging to patients in critical care settings.

Jennifer Frontera, MD: Risk of COVID-19 in Patients With Neurologic Disorders

May 02, 2020

The professor of neurology at NYU Langone discussed the risk of COVID-19 in patients with neurological disorders.

Howard Fillit, MD: The Positives of Telemedicine Adoption for Geriatric Patients

May 02, 2020

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation spoke to the way the COVID-19 pandemic has transformed the use of telemedicine for the elderly with conditions like Alzheimer and dementia.

FDA Approves Bafiertam Fumarate Bioequivalent for Relapsing Multiple Sclerosis

May 01, 2020

Banner Life Science’s novel fumarate bioequivalent alternative to Tecfidera (dimethyl fumarate; Biogen) enters the market as a new oral treatment option for relapsing forms of multiple sclerosis.

NeurologyLive Friday 5 — May 1, 2020

May 01, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 1, 2020.

Where Do Ubrogepant and the Gepant Class Fit in Migraine Care?

May 01, 2020

The director of the Montefiore Headache Center discussed recent study findings on ubrogepant and offered insight into the possible future of the gepant class in migraine.

Recommendations for Epilepsy Care During COVID-19

May 01, 2020

An emphasis on at-home care as well as reducing the risk of seizure exacerbation are among a list of notable recommendations to help optimize clinical care for patients with epilepsy amidst the COVID-19 pandemic.

Bhooma Aravamuthan, MD, DPhil: Improving Neurologists' Focus on Cerebral Palsy

May 01, 2020

The assistant professor of neurology at the University of Washington in St. Louis detailed the ­­factors that may contribute to these inconsistencies in cerebral palsy diagnosis and what role neurologists should play.

Howard Fillit, MD: The Impact of COVID-19 in Alzheimer Disease

May 01, 2020

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the effect that the COVID-19 pandemic has had on the care of patients with Alzheimer disease and dementias.

CMSC, NeurologyLive to Cohost Virtual Annual Meeting: Register Now

May 01, 2020

Educational sessions led by experts in multiple sclerosis will be held May 26-29, 2020.

Ponesimod Displays Superiority in Relapsing MS Treatment

April 30, 2020

Janssen’s S1P receptor modulator ponesimod showed its superiority to teriflunomide on annualized relapse rates, fatigue symptoms, MRI activity, brain atrophy, and NEDA-3 in patients with relapsing multiple sclerosis.

Jennifer Frontera, MD: Neurologic Symptoms of COVID-19

April 30, 2020

The professor of neurology at NYU Langone detailed the neurologic symptoms that have been observed in patients with COVID-19.

Galcanezumab Has Significant Impact for Patients With Refractory Migraine

April 30, 2020

The FDA-approved anti-CGRP therapy from Eli Lilly demonstrated a significant ability to decrease monthly migraine days in patients who did not respond to previous medications.

Jeffrey Cohen, MD: Ofatumumab's Potential Role in MS Care

April 30, 2020

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the wide variety of clinical benefits observed with ofatumumab treatment and how it fits into the MS care landscape.

Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS

April 29, 2020

Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and Collateral subscales of the Expanded Disability Status Scale.

Lasmiditan Improves Migraine-Related Disability

April 29, 2020

The FDA-approved migraine therapy lasmiditan showed long-term efficacy and had similar change in Migraine Disability Assessment total score in both 100-mg and 200-mg doses.

Bhooma Aravamuthan, MD, DPhil: Inconsistencies in Diagnosing Cerebral Palsy

April 29, 2020

The assistant professor of neurology at the University of Washington in St. Louis discussed a study she and colleagues conducted which revealed significant differences between practitioners in diagnosing cerebral palsy.

Ubrogepant More Effective in Mild Pain Migraine Attacks

April 29, 2020

Allergan’s oral CGRP antagonist showed a higher likelihood of freedom from pain and associated symptoms during mild headaches for patients with migraine compared to attacks of moderate to severe severity.

VTS-Aspirin Wins Orphan Status in Combination With Fumarates for Flush in MS

April 29, 2020

Vitalis’s VTS-Aspirin platform was granted an orphan drug designation to be used in combination with diroximel fumarate and monomethyl fumarate for the treatment of fumarate flush in relapsing multiple sclerosis.

David Langer, MD: Answering the Call for COVID-19

April 29, 2020

The chair of neurosurgery at Lenox Hill Hospital in Manhattan recently joined the ranks of health care providers who are caring for COVID-19 patients at the temporary hospital set up in the Javits Center.

Erenumab Shows Long-Term Success in Migraine Treatment

April 28, 2020

The anti-CGRP agent showed sustained benefit in reducing migraine frequency as well as good safety over 4 or more years of treatment in a cohort of more than 200 patients.

Jeffrey Cohen, MD: The Success of Ofatumumab in Relapsing MS

April 28, 2020

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the findings of a new pooled-data analysis of ofatumumab from the phase 3 ASCLEPIOS I and II trials.

Risdiplam Demonstrates Significant Motor Milestones in Infants with Type 1 SMA

April 28, 2020

In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified.

COViMS Registry Sheds Light on MS Patients With COVID-19

April 28, 2020

The Rosenthal–Trotter MS Chair in Neuroimmunology at Washington University School of Medicine in St. Louis details why the COViMS registry can serve as an important instrument for clinicians who treat patients with multiple sclerosis.

Jennifer Robblee, MD: Getting Around Telemedicine Barriers

April 28, 2020

The neurologist at the Barrow Neurological Institute detailed how she has gotten patients to buy into the adjustment to a virtual medical care model, and what challenges she's had to overcome.

Eptinezumab Improves Consecutive Migraine-Free Days, Shortens Migraine Duration

April 27, 2020

These data on the preventive migraine treatment confirmed findings from previous studies, with eptinezumab not only reducing total migraine days, but elongating the duration of consecutive migraine-free days.

Reena Mehra, MD, MS: Wearable Technologies for Sleep Apnea

April 27, 2020

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine discussed new technologies being used to diagnose and treat sleep apnea.

Epidiolex Has Safe, Consistent Profile Over Long-Term in Tuberous Sclerosis Complex

April 27, 2020

Treatment with CBD resulted in a significant number of patients with TSC reporting being “much” or “very much” improved on the Subject/Caregiver Global Impression of Change.

FDA Approves Opicapone for Parkinson Disease OFF Episodes

April 27, 2020

The COMT inhibitor helps increase ON time without promoting dyskinesia.

M. Scott Perry, MD: Clinical Experience With Fenfluramine in Dravet Syndrome

April 26, 2020

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed his experience with Zogenix’s investigational Dravet syndrome treatment in clinical trials and in the Expanded Access Program.

Optimizing Acute Migraine Care Improves Quality of Life and Reduces Disability

April 26, 2020

Data from the OVERCOME study of more than 20,000 respondents suggest that those whose acute migraine treatment was optimized according to the mTOQ had less disability and better quality of life.

Ofatumumab Displays Superiority to Teriflunomide in Relapsing MS

April 25, 2020

Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression compared to teriflunomide in relapsing multiple sclerosis.

Daridorexant Improves Daytime Sleepiness, Vutrisiran Gains Fast Track Designation, Erenumab Effective in Migraine

April 25, 2020

Neurology News Network for the week ending April 25, 2020.

M. Scott Perry, MD: Real-World Fenfluramine Data in Dravet Syndrome

April 25, 2020

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed the real-world data collected from the Expanded Access Program for fenfluramine (Fintepla; Zogenix) in patients with Dravet syndrome.

NeurologyLive Friday 5 — April 24, 2020

April 24, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

Rimegepant Shows Early Efficacy in Acute Migraine Treatment

April 24, 2020

Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose.

Jennifer Robblee, MD: Advice for Conducting Telemedicine Examinations

April 24, 2020

The neurologist at the Barrow Neurological Institute discussed her experience with telemedicine and gave advice on how to conduct examinations through audio/video platforms.

Real-World Dravet Syndrome Data Suggest Fenfluramine Provides Benefit

April 24, 2020

The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.

Post-Hoc Analysis Suggests Eptinezumab Effective for Migraine at Initial Dosing

April 24, 2020

Data confirmed the prior results of the PROMISE-1 and PROMISE-2 studies, indicating the preventive effect on migraine with eptinezumab begins as early as day 1 post-infusion.

BTK Inhibitor SAR442168 Meets Multiple Sclerosis End Points in Phase 2b

April 23, 2020

The drug's impact on neuroinflammation and neurodegeneration in the brain and spinal cord are currently being explored.

Robert E. Shapiro, MD, PhD: Takeaways From Migraine Telemedicine

April 23, 2020

The professor of neurology at the University of Vermont Larner College of Medicine detailed what lessons and highlights he’s learned from shifting his migraine care to a telemedicine-based model during the COVID-19 pandemic.

Siponimod Shows Long-Term Benefit for Secondary Progressive MS

April 23, 2020

Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.

Reena Mehra, MD, MS: Expediting Telemedicine During COVID-19

April 23, 2020

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine offered her insight on how telemedicine is being utilized to help diagnose and treat sleep disorders amidst COVID-19.

Erenumab Improves Daily Functioning and Quality of Life

April 23, 2020

The Novartis agent showed significant reduction of migraine days in both the real-world TELESCOPE and PERISCOPE studies in patients with migraine.

Robert E. Shapiro, MD, PhD: Response to AHS Special Article Pleas

April 22, 2020

The professor of neurology at the University of Vermont Larner College of Medicine discussed the response from payers and physicians to the special article he and colleagues published in the journal Headache.

Perampanel May Improve Insomnia in Patients With Epilepsy and Anxiety

April 22, 2020

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.

Shorter Ocrelizumab Infusion Time Brings Convenience, Efficiency to MS Care

April 22, 2020

The Group Medical Director of Neuroscience at Genentech discussed the shorter, 2-hour infusion time for ocrelizumab and how it might impact multiple sclerosis care as a whole.

Daridorexant Effective for Insomnia in Phase 3 Trial

April 21, 2020

The Idorsia drug candidate demonstrated minimal serious treatment-emergent adverse events, with no rebound insomnia or withdrawal symptoms upon discontinuation.

Vutrisiran Wins Fast Track Designation for Polyneuropathy in hATTR Amyloidosis

April 21, 2020

Alnylam Pharmaceuticals recently completed enrollment in the phase 3 HELIOS-A clinical trial of the drug.

Barry Byrne, MD, PhD: Going Virtual With Medical Meetings

April 21, 2020

The chief medical advisor for the Muscular Dystrophy Association discussed the switch to virtual conferences and shared his insight on how the neuromuscular community can move forward amid COVID-19.

Enhanced Paramedic Assessment in Stroke Does Not Improve Thrombolysis Volume

April 21, 2020

Observations from more than 1000 cases of stroke suggest that enhanced paramedic assessment should not be used to increase thrombolysis volume but may influence the quality of treatment decisions.

Postpartum Relapses Similar to Pre-Pregnancy Rates for Women With MS

April 20, 2020

Exclusive breastfeeding may be recommended after it was shown to reduce the risk of postpartum relapses.

COVID-19 Assistance Program Available to SMA Community

April 20, 2020

Through the new COVID-19 Assistance Program, households who have an individual with spinal muscular atrophy may be entitled to a $50 gift card to assist in costs of purchasing essential items.

Cure SMA Awards Grant to Stephen Meriney

April 20, 2020

The professor at the University of Pittsburgh was awarded a $190,000 grant for mouse model research that specifically targets neuromuscular weakness in spinal muscular atrophy.

Shorter Ocrelizumab Infusion Accepted for FDA Review

April 20, 2020

The FDA has accepted an sBLA for a version of Genentech's ocrelizumab with a shorter administration time for the treatment of relapsing and primary progressive MS.

Alon Avidan, MD: Improving Narcolepsy Management

April 20, 2020

The director of the Sleep Disorders Center and vice-chair of the department of neurology at UCLA David Geffen School of Medicine detailed the greatest need in the management of narcolepsy

Patients With Epilepsy Not Adequately Treated for Fractures and Bone Mineral Density Loss

April 20, 2020

Retrospectively analysis data suggest that while the majority of epileptics have no significant worsening in bone mineral density, they maintain an amplified risk of suffering major osteoporotic fractures.

Black Individuals With High Blood Pressure at Greater Risk for Cognitive Decline

April 18, 2020

Cumulative mean systolic blood pressure was associated with those faster declines in memory which were significantly more common in black individuals than white individuals.

Neurologic Symtpoms of COVID19, Rimegepant Available Via Telemedicine, Natalizumab

April 18, 2020

Neurology News Network for the week ending April 18, 2020.

NeurologyLive Friday 5 — April 17, 2020

April 17, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 17, 2020.

Long-Term Brivaracetam Use in Epilepsy Is Safe and Effective

April 17, 2020

Data out to 11 years suggest that individualized doses of brivaracetam (Briviact; UCB Pharma) are safe and effective in reducing focal and primary generalized seizures.

Episode 9: Innovation in the Parkinson Disease Pipeline

April 17, 2020

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Fernando Pagan, MD.

Robert E. Shapiro, MD, PhD: Migraine Care in the Era of COVID-19

April 17, 2020

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy discussed the special article he and colleagues published in the Headache journal on migraine care.

The Challenges of Stroke Care in Rural America

April 17, 2020

Stroke care, including acute treatment and prevention, faces unique challenges in rural areas where disease awareness is lacking and access to high-level care in scarce.

Diet Associated With Lower Risk of Cognitive Impairment

April 16, 2020

Consumption of whole fruits, vegetables, whole grains, nuts, legumes, fish and olive oil, as well as reduced consumption of red meat and alcohol was observed to assist in preserving cognitive function.

Abnormal White Matter Volume Conversion Linked to MS Disease Progression

April 16, 2020

In those with secondary progressive MS, evaluating diffusely abnormal white matter may provide a useful measure for therapies aiming to protect at-risk tissue, which may be able to slow progression.

Barry J. Byrne, MD, PhD: The Long-Term Impact of COVID-19 on Telemedicine

April 16, 2020

The chief medical advisor for the Muscular Dystrophy Association discussed how the ongoing novel coronavirus pandemic will have a lasting impact on the use of telemedicine in the neuromuscular community­­.

New Treatment Options Provide Relief for Migraine Sufferers

April 15, 2020

Migraine expert Teshamae Monteith, MD, describes how the University of Miami's inpatient migraine service has been a go-to resource for migraine help.

Blacks, Hispanics of Caribbean Descent Have Higher Stroke Risk Than White Neighbors

April 15, 2020

A study conducted by researchers from the University of Miami reveals a correlation with higher risk of stroke in blacks and hispanics of Caribbean descent than whites.

Tandem Gait Test Predicts Fall Risk in Early Parkinson Disease

April 15, 2020

Elevated risk of falling, an indicator of early stage Parkinson Diseas, could be predicted by a simple tandem gait test.

Miller School Hosts 'Neurology Update and Stroke Intensive Review 2020

April 15, 2020

Leaders from the University of Miami Miller School of Medicine detail the most important needs in the field of stroke and steps needed to take in 2020.

Processing Speed Test Feasible and Meaningful in Multiple Sclerosis Care

April 15, 2020

The Processing Speed Test, a tech-enabled version of the SDMT, was shown to be significantly correlated with multiple measures in routine multiple sclerosis care.

Biohaven and Cove Collaboration Provides Remote Rimegepant Access for Migraine

April 15, 2020

The CEO of Biohaven Pharmaceuticals discussed the company’s new collaboration, which has made rimegepant (Nurtec ODT) available for prescription through Cove’s telemedicine platform.

What Role Does Age Play in Multiple Sclerosis?

April 15, 2020

The director of the Multiple Sclerosis Program at Cleveland Clinic Lou Ruvo Center for Brain Health discussed the correlation between age and disease duration in MS, as well as what was learned from a subanalysis of the EXPAND study of siponimod.

Robert E. Shapiro, MD, PhD: Getting Patients Access to Migraine Care

April 15, 2020

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy discussed the need to get patients with migraine access to medications during the COVID-19 pandemic.

Alon Avidan, MD: Putting Patients With Suspected Narcolepsy Into Buckets

April 15, 2020

The Director of the Sleep Disorders Center and vice chair of the department of neurology at UCLA David Geffen School of Medicine describes why labeling patients can lead to a misdiagnosis of narcolepsy.

Acute Migraine Agent Rimegepant Available Via Cove Telemedicine Platform

April 14, 2020

Biohaven Pharmaceutical’s oral acute migraine agent rimegepant (Nurtec ODT) is the first branded medication available through Cove’s platform, which provides consults with independent health care providers and access to prescriptions.

Multiple Cranial Nerve Blocks Serve Well as Chronic Migraine Treatment

April 14, 2020

In addition to having a lowered number of headache days, around 20% of patients transformed to low-frequency, episodic migraine on follow-up.

Robert E. Shapiro, MD, PhD: Adjusting Migraine Care in a Pandemic

April 14, 2020

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy spoke about the impact the COVID-19 pandemic has had on his practice.

FDA Approves Selumetinib for Neurofibromatosis Type 1 in Pediatric Patients

April 14, 2020

Selumetinib becomes the first therapy approved for pediatric patients with Neurofibromatosis type 1.

Remote Electrical Neuromodulation Reduces Use of Migraine Medications

April 13, 2020

Incorporating remote electrical neuromodulation into the standard of care may have a positive impact on migraine management by reducing the reliance on acute medications.

Maintaining Natalizumab Treatment Through Early Pregnancy May Reduce Risk for MS Relapse

April 13, 2020

The probability of relapse and disability progression during pregnancy was associated with time when natalizumab was stopped and number of relapses in the year before natalizumab treatment.

Antisense Therapy Tominersen Holds Promise in Huntington Disease

April 13, 2020

The drug successfully demonstrated an ability to reduce mutant huntingtin protein, but the clinical benefits of that effect are yet to be determined.

PARP Pathway May Hold Promise for Parkinson Disease Treatment

April 12, 2020

Examining the underlying roles of poly adenosine diphosphate-ribose (PARP) play in the neurodegeneration of Parkinson disease.

The Evolving Landscape of Migraine Treatment

April 11, 2020

The assistant professor of Neurology, Concussion and Headache Medicine divisions, Mayo Clinic, Scottsdale, Arizona discussed the evolving migraine treatment landscape and how they have been incorporated into her practice.

Risdiplam PDUFA Pushed Back, Masitinib Gains NDA, COVID19 Affects CNS

April 11, 2020

Neurology News Network for the week ending April 11, 2020.

Neurologic Manifestations of COVID-19 Common, Report Shows

April 11, 2020

Results from one of the first multi-case studies of neurologic manifestations of COVID-19 demonstrate complex CNS involvement and raise further questions about pathological mechanism.

NeurologyLive Friday 5 — April 10, 2020

April 10, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.

Tips to Reduce Migraines Related to COVID-19 Stress

April 10, 2020

Mayo Clinic has provided advice to lower stress and anxiety amidst the COVID-19 pandemic.

Coronavirus in Multiple Sclerosis Database Launched

April 10, 2020

The COViMs website includes FAQs, a sample Case Report Form, and COVID-19 esources and will provide real-time data on patients with multiple sclerosis and other central nervous system demyeliminating diseases who have developed COVID-19.

Neuromodulation Holds Promise in Alzheimer Disease

April 10, 2020

Will ethical considerations and lack of consent stand in the way of thoroughly exploring the potential of this nondrug therapy?

High-Dose Nusinersen Trial Paves the Way for More Individualized Treatment of SMA

April 09, 2020

The director of Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, and principal investigator in the DEVOTE study discussed details of the trial and its potential impact for patients with spinal muscular atrophy.

Eptinezumab Now Available For Migraine Treatment by Prescription

April 09, 2020

Eligible commercially insured patients may pay as little as $5 per infusion every 3 months for eptinezumab through the VYEPTI Copay Assistance Program, according to Lundbeck.

The Great Debate: Can Older Patients With MS Discontinue Therapy?

April 09, 2020

As the treatment of multiple sclerosis continues to evolve and improve, the proposition of lifetime therapy has come under scrutiny.

Barry J. Byrne, MD, PhD: Remotely Managing Patients and Conducting Research

April 09, 2020

The chief medical advisor for the Muscular Dystrophy Association detailed his experience with the process of having to manage patients and conduct research amid the COVID-19 pandemic.

Treating MS: Patient Education, Pipeline Innovation, and Shared Decision-Making

April 09, 2020

The director of the MS Comprehensive Care Center at Stony Brook University discussed the need for more innovative approaches to DMTs and better communication about disease processes from physicians.

AXS-07 Meets Primary End Points, Halts Migraine Pain Progression

April 08, 2020

Phase 3 INTERCEPT data suggest the agent is successful in migraine treatment, and an NDA submission of AXS-07 in the acute treatment of migraine is on track for Q4 2020.

COVID-19: Preventive Measures in Multiple Sclerosis Patients and Others on Immuno-Modulators

April 08, 2020

Disease-modifying therapies used to treat several immune-mediated disorders in neurology may make patients more susceptible to the novel coronavirus.

Treating Tuberous Sclerosis: A Time to Shine for a Rare Disease

April 08, 2020

Elizabeth Thiele, MD, PhD, answers a variety of questions on treating tuberous sclerosis, and the landscape of treatments available at this time.

Barry J. Byrne, MD, PhD: Muscular Dystrophy Association COVID-19 Recommendations

April 08, 2020

The chief medical advisor for the Muscular Dystrophy Association spoke about the process of keeping patients updated on new information and how the MDA has taken steps to ensure the neuromuscular community gets the correct information.

Risdiplam Decision Delayed Pending New SMA Data Review

April 08, 2020

The FDA has moved the PDUFA date for risdiplam back to August 24, 2020, as the agency works to review additional data that was made available from part 2 of the pivotal SUNFISH trial.

Alon Avidan, MD, MPH: Early Stage Identification of Narcolepsy

April 08, 2020

The Director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed how patients and physicians can be proactive in identifying narcolepsy.

Building the Foundation for Precision Medicine in Epilepsy

April 07, 2020

Significant advancements in genetics and the implementation of artificial intelligence have begun to carve a new, more personalized path for the diagnosis and treatment of seizure disorders.

Gene Variants May Increase Susceptibility to Accumulate Alzheimer's Protein Tau

April 07, 2020

A Mayo Clinic Study revelead an association between inherited DNA variants and the development of tau deposits in older adults.

NARCRMS Reaches Enrollment Milestone

April 07, 2020

The North American Registry for Care and Research in MS reached a major milestone, enrolling its 750 patient in an effort to understand more about the disease course of multiple sclerosis.

Dr. Sacco Named Editor of the AHA's Stroke Journal

April 07, 2020

The world's most premier journal dedicated towards stroke and cerebrovascular health has named Ralph L. Succo, MD, MS as the new editor-in-chief.

Amino Acid Diet Leads to Lowered Risk of ALS

April 07, 2020

A pre-clinical study showed that supplementing diet with amino acid successfully staves off signs of amyotrophic lateral sclerosis.

Nerivio Migraine Device Available Through Telemedicine Platform

April 07, 2020

Patients with migraine may order the pain relief medication device directly to their homes through UpScript’s telemedicine platform.

Staccato Alprazolam Is Quick Acting in Treatment of Seizures

April 07, 2020

The director of epilepsy research and epilepsy clinical trials at NYU Langone Health’s Comprehensive Epilepsy Center spoke about the recent study findings from a trial of Staccato alprazolam.

Antiseizure Medications Show Similar Responses in Adult and Pediatric Patients

April 06, 2020

The >50% responder rate was similar between children and adults according to data from a meta-analysis of 7 clinical trials of topiramate, perampanel, and lamotrigine.

Barry J. Byrne, MD, PhD: Adjusting Care for Neuromuscular Disease Amid COVID-19

April 06, 2020

The chief medical advisor for the Muscular Dystrophy Association discussed how his approach to the management and care of patients with neuromuscular disease has been affected by the COVID-19 pandemic.

REM Sleep Behavior Disorder: Predicting Conversion to Synucleinopathy

April 06, 2020

As a marker of impending neurodegeneration, urgency surrounds efforts to slow or stop the progression of REM sleep behavior disorder.

Masitinib IND Cleared for ALS, Phase 3 Trial Set to Proceed

April 06, 2020

The phase 3 study will commence following the results of the phase 2b/3 AB10015 study, in which masitinib significantly slowed disease progression in combination with riluzole.

Solanezumab, Gantenerumab Fail to Slow Alzheimer Progression, But DIAN-TU Trial Sheds Positive Light

April 06, 2020

Despite solanezumab (Eli Lilly) and gantenerumab (Roche and Genentech) failing to meet the DIAN-TU trial primary end point in inherited Alzheimer disease, the international undertaking provided some positive takeaways for the clinical community.

Neurologic Complications of COVID-19 Reported

April 05, 2020

The first presumptive case of acute necrotizing encephalopathy in a patient with confirmed COVID-19 has been published in the journal Radiology.

Compulsive Behaviors May Be More Likely in Parkinson Disease Dementia

April 05, 2020

A multicenter, cross-sectional, observational, Spanish nationwide study’s findings suggest that those with Parkinson disease dementia may be predisposed to impulse control disorder symptoms and related behaviors.

FDA Drops Pregnancy Contraindications for Interferon Beta Products

April 04, 2020

Both the Plegridy and Avonex drug labels no longer contain the "Pregnancy Category C" classification with the report of human pregnancy registry data.

CBD Under FDA Review, Rimegepant Meets Endpoint, Sleep-Disordered Breathing Associated With Alzheimer Disease

April 04, 2020

Neurology News Network for the week ending April 4, 2020.

NeurologyLive Friday 5 — April 3, 2020

April 03, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 3, 2020.

Justifying Use of CGRP mAbs in Pediatric Patients With Migraine

April 03, 2020

What happens to the approximately 24% of pediatric patients with migraine who do not respond to the preventive treatments recommended in the AAN guidelines?

Magnetic Resonance Biomarkers Can Measure DMD Disease Progression

April 03, 2020

Prospective, observational study data suggest that MRS fat fractions and MRI quantitative T2 values can provide disease progression measures in a sensitive and noninvasive manner.